ticker,disease,stage,date,catalyst,label
SPPI,Non-Hodgkin’s lymphoma,Approved,2009-09-04 00:00:00,"Approved September 4, 2009.",1
ASRT,Postherpetic neuralgia - shingles,Approved,2011-01-28 00:00:00,"Approved January 28, 2011.",1
SPPI,Colorectal cancer,Approved,2011-04-29 00:00:00,"Approved April 29, 2011.",1
AVDL,Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery,Approved,2013-06-03 00:00:00,"Approved June 3, 2013.",1
TBPH,Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP),Approved,2013-06-21 00:00:00,"Approved June 21, 2013.",1
ABBV,Relapsed or refractory MCL mantle cell lymphoma,Approved,2013-11-13 00:00:00,"Approved November 13, 2013.",1
NVS,Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI),CRL,2014-04-30 00:00:00,CRL April 30 2014.,0
MNKD,Type 1/2 diabetes,Approved,2014-06-27 00:00:00,"Approved June 27, 2014.",1
EYPT,Diabetic macular edema,Approved,2014-09-26 00:00:00,Approved Sept 26 2014.,1
ENTA,HCV - genotype 1,Approved,2014-12-19 00:00:00,"Approved December 19, 2014.",1
VRTX,Cystic fibrosis (CF) ages 6 and older who have the R117H mutation,Approved,2014-12-29 00:00:00,"Approved December 29, 2014.",1
EBS,Anthrax,PDUFA,2015-03-25 00:00:00,"Approved March 25, 2015.",1
AMGN,Chronic Heart Failure,Approved,2015-04-15 00:00:00,"Approved April 15, 2015.",1
MNKKQ,Hemostasis,Approved,2015-04-30 00:00:00,"Approved April 30, 2015.",1
TBPH,Asthma,Approved,2015-04-30 00:00:00,"Approved April 30, 2015.",1
COLL,Pain,Approved,2015-10-25 00:00:00,"Approved October 26, 2015.",1
COLL,"Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate",Approved,2015-10-26 00:00:00,"Approved October 26, 2015.",1
CHRS,Rheumatoid arthritis,Phase 3,2016-01-11 00:00:00,"Phase 3 data released January 2016. Endpoints met. However, commercialization not possible in US before 2029 due to patent issues",0
VRTX,Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations.,CRL,2016-02-05 00:00:00,"CRL issued February 5, 2016.",0
JAZZ,Dravet Syndrome and Lennox-Gastaut syndrome,Phase 3,2016-03-14 00:00:00,"Top line Phase 3 data released March 14, 2016 met primary endpoint.",0
SPPI,Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma,Approved,2016-03-15 00:00:00,Approved March 15 2016.,1
ASRT,Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma,Approved,2016-03-15 00:00:00,Approved March 15 2016.,1
AVDL,Hypotension,Approved,2016-05-02 00:00:00,"Approved May 2, 2016.",1
LNTH,Chronic pain,Approved,2016-07-19 00:00:00,Approved July 19 2016.,1
GSK,"Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients",Approved,2016-09-02 00:00:00,"Approved September 2, 2015.",1
SRPT,Duchenne muscular dystrophy,Approved,2016-09-19 00:00:00,"Approved September 19, 2016.",1
PLXP,Mild infections of diabetic foot ulcers,Phase 3,2016-10-25 00:00:00,"Phase 3 top-line data did not meet endpoints - October 25, 2016 - TICKER CHANGED FROM DPRX FOLLOWING MERGER",1
VTVT,Type 2 Diabetes,Phase 2,2016-12-14 00:00:00,"Phase 2 primary endpoint met - December 14, 2016.",0
MACK,Cancer - HER2-positive locally advanced or metastatic breast cancer,Phase 2,2016-12-21 00:00:00,"Phase 2 trial discontinued December 21, 2016 due to poor efficacy.",-1
NBIX,Tourette syndrome - adults,Phase 2,2017-01-18 00:00:00,"Phase 2 data released January 18, 2017 did not meet primary endpoint.",1
ABBV,Marginal zone lymphoma,Approved,2017-01-19 00:00:00,"sNDA filing under priority review approved January 19, 2017.",1
AMGN,Secondary hyperparathyroidism (SHPT),Approved,2017-02-07 00:00:00,"Approved February 7, 2017.",1
NVS,HR+/HER2- advanced breast cancer,Approved,2017-03-13 00:00:00,"Priority review granted November 1, 2016. Approval announced March 13, 2017.",1
PFE,Metastatic Merkel cell carcinoma,Approved,2017-03-23 00:00:00,"Priority review announced November 29, 2016. Approval announced March 23, 2017.",1
GSK,Cancer - ovarian,Approved,2017-03-27 00:00:00,"PDUFA date under priority review was June 30, 2017. Approved March 27, 2017.",1
AZN,Epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC),Approved,2017-03-31 00:00:00,"Approval announced March 31, 2017.",1
NKTR,Bronchiectasis,Phase 3,2017-04-05 00:00:00,"Phase 3 second trial did not meet endpoint - April 5, 2017.",1
NBIX,Tardive dyskinesia,Approved,2017-04-11 00:00:00,"Approved April 11, 2017.",1
MRK,Biosimilar candidate of Remicade,Approved,2017-04-21 00:00:00,"BLA acceptance announced May 23, 2016 by partner Samsung Bioepis. Approval annuonced April 21, 2017.",1
REGN,High low-density lipoprotein (LDL) cholesterol,Approved,2017-04-25 00:00:00,"sBLA Approval announced April 25, 2017.",1
ARDX,Constipation-predominant irritable bowel syndrome (IBS-C),Phase 3,2017-05-12 00:00:00,"Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.",0
ADMP,Emergency treatment of anaphylaxis,Approved,2017-06-15 00:00:00,"CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.",1
RCKT,Glaucoma,Phase 2,2017-07-07 00:00:00,"Phase 2 trial failed - noted July 7, 2017.",-1
AMGN,Ph+ R/R ALL,Approved,2017-07-11 00:00:00,"PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.",1
AGIO,Advanced hematologic malignancies with an IDH2 mutation,Approved,2017-08-01 00:00:00,"Approval announced August 1, 2017.",1
JNJ,Second-line Chronic graft-versus-host disease (GVHD),Approved,2017-08-02 00:00:00,"Approval announced August 2, 2017.",1
ENTA,Hepatitis C virus (HCV),Approved,2017-08-03 00:00:00,"Approval announced August 3, 2017.",1
NVO,Type 1 and type 2 diabetes,Phase 3,2017-09-29 00:00:00,"Approved September 29, 2017.",1
GBT,Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest,Phase 2a,2017-10-23 00:00:00,"Phase 2a discontinuation announced October 23, 2017 due to lack of efficacy.",-1
BHC,Open angle glaucoma (OAG) or ocular hypertension (OHT),Approved,2017-11-02 00:00:00,"Approval announced November 2, 2017.",1
AZN,HPV-associated squamous cell carcinoma of the head & neck (SCCHN),Phase 1,2017-11-10 00:00:00,"Presentation at SITC Meeting - November 10, 2017.",1
ABBV,Maintenance Treatment of Schizophrenia,Approved,2017-11-13 00:00:00,"Approval announced November 13, 2017.",1
GSK,HIV,Approved,2017-11-21 00:00:00,"Approval announced November 21, 2017.",1
LLY,Psoriatic Arthritis,Approved,2017-12-01 00:00:00,"Approval announced December 1, 2017.",1
SNY,Diabetes,Approved,2017-12-11 00:00:00,"Approval announced December 11, 2017.",1
PFE,"Diffuse Large B-cell Lymphoma (DLBCL), Cutaneous T-cell lymphoma (CTCL)",Phase 1,2017-12-11 00:00:00,Phase 1a/b updated data released at ASH 2017 - 5/18 objective response rate.,0
GSK,Eosinophilic Granulomatosis with Polyangiitis (EGPA),Approved,2017-12-12 00:00:00,"Approval announced December 12, 2017.",1
INVA,Increase blood pressure in adults with septic or other distributive shock,Approved,2017-12-21 00:00:00,"Approval announced December 21, 2017.",1
AMGN,Multiple Myeloma,Approved,2018-01-05 00:00:00,"sBLA approval announced January 5, 2017.",1
SAGE,Insomnia,Phase 1/2,2018-01-31 00:00:00,"Phase 1/2 trial met primary endpoint - January 31, 2018.",0
JNJ,Non-metastatic castration-resistant prostate cancer (CRPC),Approved,2018-02-14 00:00:00,"Approval announced February 14, 2018.",1
BIIB,Mitochondrial myopathies (MM),Phase 2,2018-03-01 00:00:00,"Phase 2 initial data released March 1, 2018 - endpoints not met.",0
RETA,Mitochondrial myopathies (MM),Phase 2,2018-03-01 00:00:00,"Phase 2 initial data released March 1, 2018 - endpoints not met.",0
RARE,X-Linked Hypophosphatemia (XLH),Approved,2018-04-17 00:00:00,"Approval announced April 17, 2018.",1
NVS,Melanoma with BRAF V600E or V600K mutations,Approved,2018-04-30 00:00:00,"Approval announced April 30, 2018.",1
ABIO,Chronic Heart Failure,Phase 2b,2018-05-27 00:00:00,"Oral presentation of data May 27, 2018.",1
TXMD,Moderate-to-severe vaginal pain,Approved,2018-05-30 00:00:00,"CRL announced May 8, 2017. NDA resubmitted with approval announced May 30, 2018.",1
LLY,Rheumatoid arthritis,Approved,2018-06-01 00:00:00,"FDA approval announced for low dose only - June 1, 2018.",1
AZN,Early Alzheimer's disease,Phase 3,2018-06-11 00:00:00,Announced discontinuation of trial due to futility.,-1
MOR,Chronic Lymphocytic Leukemia,Phase 2,2018-06-15 00:00:00,Phase 2 presentation at EHA June 2018. ORR 82%. CR 9%.,1
TEVA,Cluster headache,Phase 3,2018-06-15 00:00:00,"Phase 3 trial to be terminated due to lack of efficacy - noted June 15, 2018.",-1
ARGX,Pemphigus foliaceous and vulgaris (PV),Phase 2,2018-06-20 00:00:00,"Phase 2 interim data released June 20, 2018, disease control observed in 4/6 patients.",1
SMMT,Duchenne muscular dystrophy,Phase 2,2018-06-27 00:00:00,"Phase 2 top-line data released June 27, 2018. Primary endpoint not met.",0
JNJ,Diffuse large B-cell lymphoma (DLBCL),Phase 3,2018-07-11 00:00:00,"Phase 3 trial did not meet primary endpoint - noted July 11, 2018.",1
ABBV,Endometriosis,Approved,2018-07-24 00:00:00,"FDA approval announced July 24, 2018.",1
DRRX,Schizophrenia,Approved,2018-07-27 00:00:00,"FDA Approval announced July 27, 2018.",1
REGN,Wet AMD,CRL,2018-08-13 00:00:00,"CRL issued August 13, 2018 - ongoing labeling discussions.",0
IONS,Familial chylomicronemia syndrome (FCS),CRL,2018-08-27 00:00:00,"CRL issued August 27, 2018.",0
INVA,cIAI (complicated intra-abdominal infections),Approved,2018-08-27 00:00:00,"FDA approval announced August 27, 2018.",1
GSK,Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype,CRL,2018-09-07 00:00:00,"CRL issued September 7, 2018.",0
LNTH,Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA),Phase 3,2018-09-12 00:00:00,Phase 3 trial met one of two co-primary endpoints.,0
CKPT,Non-small cell lung cancer (NSCLC),Phase 1/2,2018-09-25 00:00:00,"Phase 1/2 preliminary data released September 24, 2018.",0
RHHBY,Hemophilia,Approved,2018-10-04 00:00:00,"FDA Approval announced October 4, 2018.",1
IONS,NEURO-TTR - familial amyloid polyneuropathy (FAP).,Approved,2018-10-05 00:00:00,"FDA Approval announced October 5, 2018,",1
PFE,BRCA-mutated breast cancer,Approved,2018-10-16 00:00:00,"FDA Approval announced October 16, 2018.",1
REGN,Asthma,Approved,2018-10-19 00:00:00,"FDA approval announced October 19, 2018.",1
BIIB,Lupus,Phase 2b,2018-10-23 00:00:00,"Phase 2b data released October 23, 2018 - primary endpoint not met.",0
MACK,HER2 negative metastatic breast cancer,Phase 2,2018-11-07 00:00:00,"Phase 2 trial termination announced November 7, 2018.",-1
MESO,End-Stage Heart Failure with LVADs,Phase 2b,2018-11-11 00:00:00,"Phase 2b trial did not meet primary endpoint - November 11, 2018.",1
AZN,Lung cancer,Phase 3,2018-11-16 00:00:00,"Overall survival data also did not meet primary endpoint - November 16, 2018.",1
SGEN,Frontline CD30-positive mature T-cell lymphomas - cancer,Approved,2018-11-16 00:00:00,"FDA Approval announced November 16, 2018.",1
RHHBY,First line unfit AML,Approved,2018-11-21 00:00:00,"FDA approval announced November 21, 2018.",1
CPRX,Lambert-Easton Myasthenic Syndrome (LEMS),Approved,2018-11-28 00:00:00,"FDA approval announced November 28, 2018.",1
TEVA,Rituxan (rituximab) biosimilar,Approved,2018-11-28 00:00:00,"FDA Approval announced November 28, 2018.",1
RHHBY,Non-squamous non-small cell lung cancer (NSCLC),Approved,2018-12-06 00:00:00,"FDA Approval announced December 6, 2018.",1
NBIX,Tourette syndrome - juvenile,Phase 2b,2018-12-12 00:00:00,"Phase 2 top-line data released December 12, 2018 did not meet primary endpoint.",1
ITCI,Agitation in patients with dementia,Phase 2,2018-12-18 00:00:00,"Phase 3 interim analysis December 18, 2018 noted trial to stop due to futility.",-1
PFE,Ovarian cancer,Phase 3,2018-12-21 00:00:00,Phase 3 trial to be terminated due to lack of efficacy.,-1
OPK,Benign Prostatic Hyperplasia (BPH),Phase 2b,2019-02-01 00:00:00,"Phase 2b trial suspension announced January 31, 2019.",0
GILD,Nonalcoholic steatohepatitis (NASH),Phase 3,2019-02-11 00:00:00,"Phase 3 trial did not meet primary endpoint - February 11, 2019.",1
NVO,Hemophilia A,Approved,2019-02-19 00:00:00,"FDA Approval announced February 19, 2019.",1
MRK,Melanoma,Approved,2019-02-19 00:00:00,"FDA Approval announced February 19, 2019.",1
INDV,Bulimia Nervosa,Phase 2,2019-02-21 00:00:00,"Phase 2 data released February 21, 2019. Endpoints not met.",0
ADMP,Erectile dysfunction,NDA Filing,2019-02-26 00:00:00,"Refusal to file letter received February 26, 2019.",0
JNJ,Plaque psoriasis,Approved,2019-02-27 00:00:00,"Approval announced February 27, 2019.",1
JNJ,Treatment resistant depression,Approved,2019-03-05 00:00:00,"FDA approval announced March 5, 2019.",1
BMY,Triple-negative breast cancer,Approved,2019-03-08 00:00:00,"FDA Approval announced March 8, 2019.",1
AERI,Glaucoma,Approved,2019-03-13 00:00:00,"FDA Approval announced March 12, 2019.",1
ALT,Flu vaccine,Phase 2,2019-03-19 00:00:00,"Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected.",0
GSK,HIV,Approved,2019-04-08 00:00:00,"FDA approval announced April 8, 2019.",1
AMGN,Osteoporosis,Approved,2019-04-09 00:00:00,"FDA Approval announced April 9, 2019.",1
JNJ,Urothelial cancer,Approved,2019-04-12 00:00:00,"FDA Approval announced April 12, 2019.",1
AXSM,Smoking cessation,Phase 2,2019-04-15 00:00:00,"Phase 2 top-line data met primary endpoint - April 15, 2019.",0
MRK,Renal cell carcinoma,Approved,2019-04-22 00:00:00,"FDA approval announced April 22, 2019.",1
SNY,Dengue,Approved,2019-05-01 00:00:00,"FDA approval announced May 1, 2019.",1
NVS,"Pre-symptomatic patients with spinal muscular atrophy (SMA) Types 1, 2 and 3",Phase 3,2019-05-05 00:00:00,"Phase 3 data May 5, 2019 noted all patients (18/18) were alive and event-free",0
PFE,Transthyretin amyloid cardiomyopathy (ATTR-CM),Approved,2019-05-06 00:00:00,"FDA approval announced May 6, 2019.",1
PRVB,Ulcerative Colitis,Phase 1b,2019-05-08 00:00:00,"Phase 1b top-line data May 8, 2019 noted primary safety and tolerability endpoint met but secondary efficacy endpoints were not met.",1
CMRX,Allogeneic hematopoietic stem cell transplant (HCT) recipients with adenovirus (AdV),Phase 2,2019-05-09 00:00:00,"Phase 2 trial discontinued - May 9, 2019.",-1
LLY,Hepatocellular Carcinoma,Approved,2019-05-13 00:00:00,"FDA approval announced May 13, 2019.",1
MGTX,RPE65-Deficiency,Phase 1/2,2019-05-14 00:00:00,Phase 1/2 data met primary endpoint of safety and tolerability.,1
ABBV,Chronic Lymphocytic Leukemia,Approved,2019-05-15 00:00:00,"FDA approval announced May 15, 2019.",1
MRK,Triple negative breast cancer (TNBC),Phase 3,2019-05-20 00:00:00,"Phase 3 data May 20, 2019 did not meet primary endpoint.",1
INCY,Graft versus host disease,Approved,2019-05-24 00:00:00,"FDA approval announced May 24, 2019.",1
MRK,Hospital-acquired bacterial pneumonia (HABP),Approved,2019-06-03 00:00:00,"FDA approval announced June 3, 2019.",1
RHHBY,Diffuse large B-cell lymphoma (DLBCL),Approved,2019-06-10 00:00:00,"FDA approval announced June 10, 2019.",1
AMGN,Herceptin biosimilar,Approved,2019-06-13 00:00:00,"FDA approval announced June 13, 2019.",1
ABBV,Upper limb spasticity,Approved,2019-06-21 00:00:00,"FDA Approval announced June 21, 2019.",1
VRTX,Cystic fibrosis - Two Copies of the F508del Mutation,Approved,2019-06-21 00:00:00,"Label expanded to now include all patients over 6 years old - June 21, 2019.",0
ATOS,Mammographic breast density (MBD),Phase 2,2019-06-27 00:00:00,"Phase 2 data met primary endpoint - June 27, 2019. High dropout rate noted.",0
GMAB,Newly Diagnosed Multiple Myeloma (NDMM),Approved,2019-06-28 00:00:00,"FDA Approval announced June 28, 2019.",1
PFE,Persistent Pulmonary Hypertension (PPHN),Phase 3,2019-06-28 00:00:00,"Phase 3 trial did not meet primary endpoint - June 28, 2019.",1
ITCI,Bipolar depression,Phase 3,2019-07-08 00:00:00,"Phase 3 trial did not meet primary endpoint - July 8, 2019.",1
AMGN,Behçet’s Disease,Approved,2019-07-19 00:00:00,"FDA Approval announced July 19, 2019.",1
TAK,Crohn's Disease,Phase 3,2019-07-22 00:00:00,"Phase 3 trial met primary endpoint - July 22, 2020.",0
LGND,Postpartum depression,Phase 2,2019-07-23 00:00:00,"Phase 2 negative data released July 23, 2019.",0
ALKS,Relapsing Remitting Multiple Sclerosis (RRMS),Phase 3,2019-07-30 00:00:00,"Phase 3 top-line data met primary endpoint - July 30, 2019.",0
VNDA,Jet Lag Disorder,CRL,2019-08-19 00:00:00,"CRL issued August 19, 2019.",0
NBRV,Moderate to severe Community Acquired Bacterial Pneumonia (CABP),Approved,2019-08-19 00:00:00,"FDA approval announced August 19, 2019.",1
TVTX,Pantothenate kinase-associated neurodegeneration (PKAN),Phase 3,2019-08-22 00:00:00,"Phase 3 top-line data did not meet endpoints - August 22, 2019.",1
LLY,Axial Spondyloarthritis,Approved,2019-08-26 00:00:00,"FDA Approval announced August 26, 2019.",1
XERS,Severe hypoglycemia,Approved,2019-09-10 00:00:00,"FDA Approval issued September 10, 2019.",1
BIIB,Alzheimer’s disease,Phase 3,2019-09-13 00:00:00,Phase 3 trial discontinued due to unfavorable risk-benefit ratio.,1
MRK,Endometrial cancer,Approved,2019-09-17 00:00:00,"FDA Approval announced September 17, 2019.",1
GILD,Pre-exposure prophylaxis,Approved,2019-10-03 00:00:00,"FDA Approval announced October 3, 2019.",1
VYNE,Acne,Approved,2019-10-18 00:00:00,"FDA Approval announced October 18, 2019.",1
RHHBY,Influenza,Approved,2019-10-18 00:00:00,"FDA Approval announced October 18, 2019.",1
CPRX,Congenital Myasthenic Syndromes (CMS),Phase 3,2019-10-30 00:00:00,"Phase 3 trial did not meet primary endpoint - October 30, 2019.",1
OBSV,Improving IVF outcomes,Phase 3,2019-11-06 00:00:00,"Phase 3 trial did not meet primary endpoint - November 10, 2019.",1
IBRX,Merkel cell carcinoma (MCC),Phase 2,2019-11-07 00:00:00,"Phase 2 data noted 2/7 responses (1 PR / 1 CR) - November 7, 2019.",0
ALNA,Enteric Hyperoxaluria,Phase 3,2019-11-07 00:00:00,"Phase 3 trial met primary endpoint, key secondary endpoint missed - November 7, 2019.",0
PFE,Gastric cancer,Phase 3,2019-11-08 00:00:00,"Phase 3 endpoint not met - November 8, 2019.",0
BMY,"Urothelial carcinoma, Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers",Phase 1/2,2019-11-09 00:00:00,"Phase 1/2 updated data at SITC November 9, 2019 noted ORR was 53% (20/38) with 34% (13/38) complete response (CR) rate.",0
VTGN,Adjunctive Treatment Major Depressive Disorder,Phase 2,2019-11-14 00:00:00,"Phase 2 data did not meet primary endpoint - November 14, 2019.",1
MOR,Relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL),Phase 3,2019-11-18 00:00:00,"Phase 3 futility analysis passed November 18, 2019",0
EBS,Chikungunya virus,Phase 2,2019-11-22 00:00:00,"Phase 2 interim analysis noted 98% of study participants produced a neutralizing antibody response against the chikungunya virus (CHIKV) within seven days after vaccination - November 22, 2019.",0
GBT,Sickle cell disease,Approved,2019-11-25 00:00:00,"FDA Approval announced November 25, 2019.",1
CARA,Stage 3-4 Chronic Kidney Disease-Associated Pruritus,Phase 2,2019-12-03 00:00:00,"Phase 2 data met primary endpoint but secondary missed - December 3, 2019.",0
MRK,Myelofibrosis,Phase 2,2019-12-09 00:00:00,Phase 2 data at ASH December 2019 noted primary endpoint met in 10%~32% of patients across four cohorts.,0
SRPT,Duchenne muscular dystrophy,Approved,2019-12-12 00:00:00,"FDA Approval announced December 12, 2019.",1
GILD,Nonalcoholic steatohepatitis (NASH),Phase 2,2019-12-16 00:00:00,"Phase 2 trial did not meet primary endpoint - December 16, 2019.",1
BHC,Acne,Approved,2019-12-19 00:00:00,"FDA Approval announced December 19, 2019.",1
INCY,Treatment-naïve acute GVHD,Phase 3,2020-01-02 00:00:00,"Phase 3 trial did not meet primary endpoint - January 2, 2020.",1
BPMC,PDGFRA exon 18 mutant Gastrointestinal stromal tumors (GIST),Approved,2020-01-09 00:00:00,"FDA Approval announced January 9, 2020.",1
OYST,Dry eye disease,Phase 2,2020-01-12 00:00:00,"Phase 2 top-line data met primary endpoint - January 12, 2020.",0
ELOX,Cystinosis,Phase 2,2020-01-14 00:00:00,"Phase 2 data released January 14, 2020.",0
RHHBY,Urothelial cancer,Phase 3,2020-01-24 00:00:00,"Phase 3 trial did not meet primary endpoint - January 24, 2020.",1
SNY,Multiple sclerosis,Phase 2,2020-02-06 00:00:00,"Phase 2 data met primary endpoint - February 6, 2020. Data to be presented at upcoming meeting.",1
LLY,Inherited Alzheimer's disease,Phase 2/3,2020-02-10 00:00:00,Phase 3 trial did not meet primary endpoint.,1
RHHBY,Inherited Alzheimer's disease,Phase 2/3,2020-02-10 00:00:00,Phase 3 trial did not meet primary endpoint.,1
BHVN,Generalized anxiety disorder (GAD),Phase 3,2020-02-10 00:00:00,Phase 3 trial did not meet primary endpoint.,1
MRTX,Renal cell carcinoma (RCC),Phase 1/2,2020-02-15 00:00:00,"Phase 2 updated data presented at ASCO GU 2020. 15/38 (39%) partial response rate, PFS 10.3 months - February 15, 2020.",1
ESPR,Hypercholesterolemia,Approved,2020-02-21 00:00:00,"FDA Approval announced February 21, 2020.",1
PFE,Acute treatment of migraine,Approved,2020-02-27 00:00:00,"FDA Approval announced February 27, 2020.",1
BMY,Previously Treated Hepatocellular Carcinoma,Approved,2020-03-11 00:00:00,"FDA Approval announced March 11, 2020.",1
IGXT,Migraine,CRL,2020-03-27 00:00:00,"CRL announced March 27, 2020.",0
IMVT,Graves Ophthalmopathy,Phase 2a,2020-03-30 00:00:00,"Phase 2a initial data March 30, 2020 noted 65% mean reduction in total IgG.",1
MRK,Myelodysplastic syndromes (MDS) cancer,Approved,2020-04-03 00:00:00,"FDA Approval announced April 3, 2020.",1
URGN,Urothelial Carcinoma,Approved,2020-04-15 00:00:00,"FDA Approval announced April 15, 2020.",1
INCY,Cholangiocarcinoma,Approved,2020-04-17 00:00:00,"FDA Approval announced April 17, 2020.",1
BIIB,Epilepsy,Phase 2,2020-04-22 00:00:00,Phase 2 primary endpoint not met.,0
NBIX,Parkinson's disease,Approved,2020-04-27 00:00:00,"FDA Approval announced April 27, 2020.",1
VCNX,Non-small cell lung cancer (NSCLC),Phase 1/2,2020-04-27 00:00:00,"Phase 1/2 updated data presented April 27, 2020 at AACR noted 81% of immunotherapy-naïve patients (17/21) experienced disease control - partial response (5/21 patients) or stable disease (12/21 patients)",1
UTHR,Pulmonary Arterial Hypertension (PAH),CRL,2020-04-28 00:00:00,"CRL announced April 29, 2020.",0
SUPN,Bipolar depression,Phase 3,2020-05-05 00:00:00,"Phase 3 development has been terminated - May 5, 2020.",-1
AZN,Heart failure,Approved,2020-05-05 00:00:00,"FDA Approval announced May 5, 2020.",1
INCY,Non-small cell lung cancer,Approved,2020-05-06 00:00:00,"FDA Approval announced May 6, 2020.",1
MRK,First-line ovarian cancer,Approved,2020-05-08 00:00:00,"FDA Approval announced May 8, 2020.",1
KNSA,Chronic Pruritus,Phase 2,2020-05-11 00:00:00,"Phase 2 interim data released May 11, 2020.",0
CLVS,Castrate-resistant prostate cancer (mCRPC),Approved,2020-05-15 00:00:00,"FDA Approval announced May 15, 2020.",1
AZN,Castration-Resistant Prostate Cancer,Approved,2020-05-19 00:00:00,"FDA Approval announced May 19, 2020.",1
GILD,Ulcerative colitis,Phase 2/3,2020-05-20 00:00:00,"Phase 2b/3 data released May 20, 2020. 200mg dose met primary endpoint. 100mg did not meet clinical remission endpoint.",1
EVFM,contraceptive vaginal gel,Approved,2020-05-22 00:00:00,"FDA Approval announced May 22, 2020.",1
REGN,Atopic dermatitis 6-11 year-olds,Approved,2020-05-26 00:00:00,"FDA Approval announced May 26, 2020.",1
NBIX,Uterine Fibroids,Approved,2020-05-29 00:00:00,"FDA approval announced May 29, 2020.",1
PFE,Early stage breast cancer,Phase 3,2020-05-29 00:00:00,"Phase 3 trial unlikely to show a statistically significant improvement in the primary endpoint following futility analysis - May 29, 2020.",1
LLY,Non-radiographic axial spondyloarthritis,Approved,2020-06-01 00:00:00,"FDA Approval announced June 1, 2020.",1
ITRM,Complicated urinary tract infections (cUTI),Phase 3,2020-06-01 00:00:00,"Phase 3 data did not meet primary endpoint - June 1, 2020.",1
BLUE,TDT and the β0/β0genotype,Phase 3,2020-06-11 00:00:00,"Phase 3 updated data at EHA June 12, 2020. Six of eight evaluable patients achieved transfusion independence,",1
BGNE,Waldenström’s macroglobulinemia,Phase 1/2,2020-06-12 00:00:00,"Phase 1/2 updated data at EHA 2020 noted overall response rate (ORR) was 80%, with a complete response (CR) rate of 15% and a partial response (PR) rate of 65%.",0
XERS,Exercise-Induced Hypoglycemia,Phase 2b,2020-06-15 00:00:00,"Phase 2b trial met primary endpoints - June 15, 2020.",0
RVNC,Forehead lines,Phase 2,2020-06-30 00:00:00,"Phase 2 data noted 100% of subjects achieved a score of none or mild wrinkle or line severity at Week 4 in at least one treatment group - June 30, 2020.",1
RVNC,Lateral Canthal (Crow’s Feet) Lines,Phase 2,2020-06-30 00:00:00,"Phase 2 top-line data released June 30, 2020. 88% of subjects achieved a score of none or mild wrinkle or line severity at Week 4 in at least one treatment group.",1
SNY,Coronavirus COVID-19,Phase 3,2020-07-02 00:00:00,"Phase 3 trial did not meet primary endpoint - July 2, 2020.",1
JNJ,Psoriatic Arthritis,Approved,2020-07-14 00:00:00,"FDA Approval announced July 14, 2020.",1
JAZZ,Cataplexy and Excessive Daytime Sleepiness in Narcolepsy,Approved,2020-07-22 00:00:00,"FDA Approval announced July 22, 2020.",1
AZN,Chronic obstructive pulmonary disease (COPD),Approved,2020-07-24 00:00:00,"FDA approval announced July 24, 2020.",1
INCY,Relapsed or refractory diffuse large B cell lymphoma,Approved,2020-07-31 00:00:00,"FDA Approval announced July 31, 2020.",1
PTCT,Spinal Muscular Atrophy (SMA) Type 1,Approved,2020-08-07 00:00:00,"FDA Approval announced August 7, 2020.",1
TRVN,Moderate to severe acute pain,Approved,2020-08-07 00:00:00,"FDA Approval announced August 7, 2020.",1
EGRX,Exertional heat stroke (EHS),CRL,2020-08-10 00:00:00,"CRL announced August 10, 2020.",0
VTRS,Multiple sclerosis - Tecfidera generic,Approved,2020-08-17 00:00:00,"FDA approved August 17, 2020.",1
GLPG,Systemic sclerosis,Phase 2,2020-09-10 00:00:00,"Phase 2 trial met primary endpoint - September 10, 2020.",0
BGNE,Non-squamous non-small cell lung cancer (NSCLC),Phase 3,2020-09-17 00:00:00,Phase 3 primary endpoint met - PFS 9.7 months in Arm A compared to 7.6 months in the chemotherapy alone Arm B (p=0.0044; stratified hazard ratio [HR]=0.64.,0
INCY,Anal cancer,Phase 2,2020-09-18 00:00:00,Phase 2 data noted objective response rate of 14% and disease control rate of 49%.,0
AERI,Open Angle Glaucoma,Phase 3,2020-09-24 00:00:00,"Phase 3 top-line data released September 24, 2020. Non-inferiority to Ganfort achieved.",1
ETON,Allergic conjunctivitis,Approved,2020-09-25 00:00:00,"FDA approval announced September 25, 2020.",1
PFE,Juvenile idiopathic arthritis (JIA),Phase 3,2020-09-28 00:00:00,"FDA approval announced September 28, 2020.",1
KNSA,Giant cell arteritis (GCA),Phase 2,2020-10-06 00:00:00,"Phase 2 trial met endpoints - October 6, 2020.",0
CANF,Rheumatoid arthritis,Phase 2,2020-10-06 00:00:00,"Phase 3 interim analysis recommended trial to be discontinued - October 6, 2020.",-1
REGN,Ebola,Approved,2020-10-14 00:00:00,"FDA Approval announced October 14, 2020.",1
MRK,Classical Hodgkin lymphoma,Approved,2020-10-15 00:00:00,"FDA Approval announced October 15, 2020.",1
SCNI,Universal flu vaccine,Phase 3,2020-10-23 00:00:00,"Phase 3 trial did not meet endpoints - October 23, 2020.",1
MRTX,Colorectal Cancer,Phase 1/2,2020-10-25 00:00:00,Phase 1/2 updated data noted (23/51) 45% ORR in NSCLC patients.,0
AUPH,Dry eye syndrome,Phase 2/3,2020-11-02 00:00:00,"Phase 2/3 trial did not meet primary endpoint - November 2, 2020. Development to be suspended.",1
AZN,Acute ischaemic stroke,Approved,2020-11-06 00:00:00,"FDA approval announced November 6, 2020.",1
BLPH,COVID-19,Phase 3,2020-11-23 00:00:00,"Phase 3 trial placed on clinical hold - November 23, 2020.",0
VTRS,Pediatric Formulation of Dolutegravir (DTG),Approved,2020-11-23 00:00:00,"FDA tentative approval announced November 23, 2020.",1
ALNY,Primary Hyperoxaluria Type 1 (PH1),Approved,2020-11-24 00:00:00,"FDA approval announced November 24, 2020.",1
RYTM,POMC deficiency obesity / Leptin Receptor Deficiency Obesity,Approved,2020-11-27 00:00:00,"FDA approval announced November 27, 2020.",1
ERYP,Acute lymphoblastic leukemia (ALL),Phase 2,2020-12-06 00:00:00,"Phase 2 data presented at ASH December 6, 2020. Endpoints met.",1
EVLO,Colorectal cancer; Triple-negative breast cancer,Phase 2,2020-12-09 00:00:00,"Phase 1/2 data to be presented at SABSC December 9, 2020 - objective response rate (ORR) of 18%.",1
AADI,Open-angle glaucoma (OAG),Phase 2,2020-12-11 00:00:00,Phase 2 data met primary endpoint with twice-daily dose group but not with once-daily group.,0
AMGN,RITUXAN biosimilar - non-Hodgkin lymphoma,Approved,2020-12-17 00:00:00,"FDA approval announced December 17, 2020.",1
RVNC,Upper facial lines,Phase 2,2020-12-17 00:00:00,Efficacy of none or mild wrinkle severity seen in greater than 92% of subjects after four weeks.,0
GSK,Lupus Nephritis,Approved,2020-12-17 00:00:00,"FDA approval announced December 17, 2020.",1
TAK,Chronic Myeloid Leukemia,Approved,2020-12-18 00:00:00,"FDA approval announced December 18, 2020.",1
MYOV,Advanced prostate cancer,Approved,2020-12-18 00:00:00,"FDA approval announced Decmber 18, 2020.",1
NBIX,Parkinson's Disease,Phase 2,2020-12-22 00:00:00,"Phase 2 trial placed on clinical hold - December 22, 2020.",0
KNSA,COVID-19,Phase 2,2020-12-22 00:00:00,"Phase 2 trial did not meet primary endpoint - December 22, 2020.",1
CALA,Renal cell carcinoma,Phase 2,2021-01-04 00:00:00,"Phase 2 top-line data did not meet primary endpoint - January 4, 2021.",1
LIFE,COVID-19,Phase 2,2021-01-04 00:00:00,"Phase 2 data released January 4, 2021. Primary safety endpoint met. Median time to recovery of 5.5 days compared to 6 days in the placebo group.",0
BMY,Relapsed or refractory (R/R) large B-cell lymphoma,Approved,2021-02-05 00:00:00,"FDA approval announced February 5, 2021.",1
AGEN,Solid tumors,Phase 1/2,2021-02-09 00:00:00,"Phase 1/2 data announced February 9, 2021 - six confirmed responses.",0
ABBV,Neurogenic Detrusor Overactivity,Approved,2021-02-10 00:00:00,"FDA approval announced February 10, 2021.",1
GTHX,Second/third-line small-cell lung cancer,Approved,2021-02-12 00:00:00,"FDA approval announced February 12, 2021.",1
SCYX,Candida Auris,Phase 3,2021-03-02 00:00:00,"Phase 3 interim analyses noted 8/10 complete responses - March 2, 2021.",0
APLS,COVID-19 / Acute respiratory distress syndrome (ARDS),Phase 1/2,2021-03-04 00:00:00,Phase 1/2 trial to be discontinued following Independent data monitoring committee (DMC) review which found no meaningful reduction in the overall mortality rate.,1
ANAB,Palmo-plantar pustular psoriasis,Phase 2,2021-03-08 00:00:00,"Phase 2 trial did not meet primary endpoint - March 8, 2021.",1
AVEO,Third line treatment of patients with renal cell cancer,Approved,2021-03-10 00:00:00,"FDA approval announced March 10, 2021.",1
BLUE,Childhood cerebral adrenoleukodystrophy (CCALD),Phase 2/3,2021-03-14 00:00:00,"Phase 2/3 updated data presented March 15, 2021. 90% of evaluable patients (27/30) alive and free of major functional disabilities at two years follow-up.",1
SNY,Cystic fibrosis,Phase 1/2,2021-03-17 00:00:00,"Phase 1/2 interim analysis March 17, 2021. Safe and well tolerated with no serious adverse events but no increase in lung function (ppFEV1) evident.",1
KNSA,Pericarditis,Approved,2021-03-18 00:00:00,"FDA approval announced March 18, 2021.",1
VACC,COVID-19 vaccine,Phase 3,2021-03-22 00:00:00,"Data from U.S. trial noted 76% efficacy rate - March 24, 2021.",0
PRQR,Usher Syndrome Type 2,Phase 1/2,2021-03-24 00:00:00,"Phase 1/2 data released March 24, 2021. Mean benefit of 6 letters was observed at week 48",1
BLUE,Relapsed/refractory multiple myeloma,Approved,2021-03-26 00:00:00,"FDA approval announced March 26, 2021.",1
SNY,Refractory Multiple Myeloma,Approved,2021-03-31 00:00:00,"FDA approval announced March 31, 2021.",1
SUPN,ADHD,Approved,2021-04-02 00:00:00,"FDA approval announced April 2, 2021.",1
BMY,RET-altered NSCLC,Phase 1/2,2021-04-05 00:00:00,"Phase 1/2 interim data noted 3/14 partial responses - April 5, 2021.",0
MTEM,Relapsed/refractory diffuse large B-cell lymphoma (DLBCL),Phase 2,2021-04-05 00:00:00,"Development to be discontinued - April 5, 2021.",-1
SAGE,Essential tremor,Phase 2,2021-04-12 00:00:00,"Phase 2 trial met primary endpoint (P=0.049) - April 12, 2021. 62% of patients were down-titrated to from 60mg to 45 mg or 30 mg with the high dose not well tolerated.",1
OVID,Fragile X syndrome,Phase 2,2021-04-19 00:00:00,"Development to be discontinued - April 19, 2021.",-1
VRNA,COVID-19,Phase 2,2021-04-23 00:00:00,"Phase 2 top-line data released April 23, 2021 - safe and well tolerated. One patient death was reported in the ensifentrine treatment group.",1
IMAB,Ulcerative colitis,Phase 2,2021-04-26 00:00:00,Phase 2 trial met primary endpoint.,0
SRPT,Duchenne muscular dystrophy,Phase 2,2021-05-03 00:00:00,"Phase 2 30 mg/kg arm data presented May 3, 2021 - mean exon skipping of 10.79% and mean dystrophin expression of 6.55%.",1
FATE,Acute graft-versus-host disease (GvHD) undergoing hematopoietic cell transplantation (HCT),Phase 2,2021-05-05 00:00:00,Phase 2 trial did not meet primary endpoint.,1
BMY,Esophageal or Gastroesophageal Junction Cancer,Approved,2021-05-20 00:00:00,"FDA approval announced May 20, 2021.",1
BMY,Ulcerative Colitis,Approved,2021-05-27 00:00:00,"FDA approval announced May 27, 2021.",1
LMNL,Idiopathic pulmonary fibrosis (IPF),Phase 2,2021-05-28 00:00:00,"Phase 2 trial will no longer be initiated - May 28, 2021.",0
BBIO,Cholangiocarcinoma,Approved,2021-06-01 00:00:00,"FDA approval announced June 1, 2021.",1
ACIU,Alzheimer’s disease (AD),Phase 2,2021-06-02 00:00:00,"Phase 2 interim analysis June 2, 2021. Good safety confirmed.",0
BIIB,Alzheimer’s disease,Approved,2021-06-07 00:00:00,"FDA approval announced June 7, 2021.",1
PFE,Pneumococcal conjugate vaccine (18 yrs +),Approved,2021-06-08 00:00:00,https://www.businesswire.com/news/home/20210608006149/en/,0
BPMC,Advanced Systemic mastocytosis (SM),Approved,2021-06-16 00:00:00,"FDA approval announced June 16, 2021.",1
TBPH,Acute Lung Injury (ALI) caused by COVID-19,Phase 2,2021-06-21 00:00:00,"Phase 2 trial did not meet primary endpoint - June 21, 2021.",1
GLTO,COVID-19,Phase 2,2021-06-22 00:00:00,"Phase 2 top-line data released June 22, 2021. Will focus resources on other pipeline treatments.",1
ADCT,Hodgkin lymphoma (HL),Phase 2,2021-06-22 00:00:00,"Phase 2 interim data presented June 22, 2021. Overall response rate (ORR) was 66.3% (67/101 patients) with a complete response rate (CRR) of 27.7% and partial response rate (PRR) of 38.6%. Median duration of response has not been reached.",1
AGTC,Achromatopsia,Phase 1/2,2021-06-24 00:00:00,"Phase 1/2 12-month data presented June 24, 2021. Company noted at this time point consistent evidence not shown of biologic activity, patient-reported anecdotes continue to be encouraging.",1
ALT,COVID-19,Phase 1/2,2021-06-29 00:00:00,"Phase 1/2 enrollment to be terminated - June 29, 2021.",-1
VCEL,Severe burns,CRL,2021-06-29 00:00:00,"CRL announced June 29, 2021.",0
MRK,Cutaneous squamous cell carcinoma (cSCC),Approved,2021-07-06 00:00:00,"FDA approval announced July 6, 2021.",1
SCPH,Heart Failure,Phase 3,2021-07-13 00:00:00,"Phase 3 data released July 13 2021, study halted early due to highly statistical reduction in costs of $17,753 (p<0.0001) per study subject",1
LLY,Atopic dermatitis,PDUFA,2021-07-16 00:00:00,"Noted FDA will not meet assigned July 2021 PDUFA date - July 16, 2021",1
PALI,Bowel Function Following Abdominal Surgery,Phase 2,2021-07-29 00:00:00,"Phase 2 data released July 29, 2021- statistically significant (p=0.0008) effect in accelerating the return of bowel function.",0
CLNN,Parkinson's Disease,Phase 2,2021-08-05 00:00:00,"Phase 2 trial met primary endpoint - August 5, 2021.",0
FGEN,Anaemia in Chronic Kidney Disease,CRL,2021-08-11 00:00:00,"CRL announced August 11, 2021.",0
PFE,Tick-borne encephalitis (TBE) vaccine,Approved,2021-08-13 00:00:00,"FDA Approval announced August 13, 2021",1
GSK,Mismatch repair deficient (dMMR) solid tumors,Approved,2021-08-17 00:00:00,"FDA Approval announced August 27, 2021.",1
MRNS,Tuberous Sclerosis Complex,Phase 2,2021-08-17 00:00:00,"Phase 2 top-line data released August 17, 2021. Primary endpoint showed a median 16.6% reduction in 28-day seizure frequency relative to baseline.",1
CARA,Chronic kidney disease (CKD) on hemodialysis (HD) with Moderate-to Severe Pruritus,Approved,2021-08-23 00:00:00,"FDA approval announced August 23, 2021.",1
PFE,Atopic dermatitis,Phase 3,2021-08-30 00:00:00,Phase 3 trial met its co-primary and key secondary efficacy endpoints.,0
MRK,Bladder cancer,Approved,2021-08-31 00:00:00,"FDA approval announced August 31, 2021.",1
TAK,"Higher-risk myelodysplastic syndromes (HR-MDS), chronic myelomonocytic leukemia (CMML) and low-blast acute myeloid leukemia (AML)",Phase 3,2021-09-01 00:00:00,"Phase 3 data did not meet primary endpoint September 1, 2021.",1
AZN,Asthma and comorbid nasal polyps,Phase 3,2021-09-05 00:00:00,"Phase 3 data showed an 86% reduction in the annualized asthma exacerbation rate (AAER) September 5, 2021.",1
SLNO,Prader-Willi syndrome (PWS),Phase 3,2021-09-08 00:00:00,"Phase 3 extension study data showed mean (SE) improvement in hyperphagia by a decrease in the HQ-CT total score, of -9.9 (0.77), was highly significant (p<0.0001) after receiving DCCR for 52 weeks, noted September 8, 2021.",1
BGNE,Marginal Zone Lymphoma,Approved,2021-09-15 00:00:00,"Approved September 15, 2021.",1
JNJ,Prostate Cancer,Phase 3,2021-09-16 00:00:00,"Phase 3 data showed OS was improved by abiraterone both in the overall population (HR: 0.83; medians: 5.7 vs 4.7 yrs) and in the ADT+ docetaxel population (HR: 0.75; medians: NR vs 4.4 yrs), noted September 16, 2021.",1
BMY,First-line Renal cell carcinoma (RCC),Phase 3,2021-09-16 00:00:00,"Additional Phase 3 survival data released at ESMO September 16, 2021. Nearly half of patients treated with the dual immunotherapy combination were alive at five years from the start of therapy. Opdivo plus Yervoy continued to show durable responses, with the median duration of response not reached among all randomized patients after five years of follow-up.",1
AZN,Gastric cancer,Phase 2,2021-09-17 00:00:00,"Phase 2 trial data showed confirmed overall response rate (ORR) of 38% as assessed by independent central review (ICR). Three (3.8%) complete responses (CR) and 27 (34.2%) partial responses (PR) were observed in patients treated with ENHERTU, September 17, 2021.",1
MRTX,Nonsquamous (NSQ) Non–Small-Cell Lung Cancer (NSCLC),Phase 2,2021-09-20 00:00:00,"Phase 2 data demonstrated that the median PFS was 5.7 months and the median overall survival (OS) was 14.9 months, with 56% and 32% of these patients alive at one year and two years, respectively. ORR was 18%, with 3% CR and 15% PR. The median DOR was 12.8 months, presented at ESMO September 20, 2021.",1
LGVN,Aging Frailty,Phase 2b,2021-09-29 00:00:00,"Phase 2b biomarker data showed Lomecel-B had statistically significant reduction in serum levels of soluble TIE-2 in a dose-dependent fashion at Day 270 compared to placebo. The levels fell by -243.13 ± 1073.21 pg/mL compared to an increase of 356.03 ± 1018.95 pg/mL in the placebo group, noted September 29, 2021.",1
RHHBY,COVID-19 (Anti-viral antibody),Phase 2/3,2021-09-30 00:00:00,"Phase 3 trial met primary endpoint, with 36% reduced risk of death by day 29, and 56% reduced risk in patients who were seronegative. Of 2,007 patients (REGEN-COV=1,340, placebo=667) serious adverse events occurred in 21% REGEN-COV patients and 26% placebo patients, noted September 30, 2021.",1
ARQT,Plaque psoriasis,Phase 3,2021-09-30 00:00:00,"Phase 3 data met its primary endpoint of Investigator Global Assessment Success rate at week 8 in 37.5% compared to a vehicle rate of 6.9%, noted September 30, 2021.",0
ARQT,Scalp psoriasis,Phase 2,2021-09-30 00:00:00,"Phase 2 study met its primary endpoint with a Scalp-Investigator Global Assessment success rate of 59.1% patients compared to a vehicle rate of 11.4% (P<0.0001). Of these, 34.3% of patients on roflumilast foam achieved a status of clear - noted September 30, 2021.",1
GILD,Adult patients with r/r ALL - cancer,Approved,2021-10-01 00:00:00,"Approved October 1, 2021.",1
LABP,Ulcerative Colitis,Phase 2,2021-10-04 00:00:00,"Phase 2 data displayed clinical remission in 36.1% of the 880 mg group and 35.5% of the 440 mg group during the blinded maintenance phase. Both dose cohorts had 10% of patients report an AE of ulcerative colitis worsening, noted October 4, 2021.",0
TCON,Mesothelioma cancer,Phase 2,2021-10-07 00:00:00,"Phase 2 data reported that 9 patients reported stable disease as best response with Grade 3 TRAEs including lymphopenia (4) and anemia (1), noted October 7, 2021.",0
FRTX,Axillary hyperhidrosis,Phase 3,2021-10-07 00:00:00,"Phase 3 study demonstrated that dosing was generally well-tolerated, the proportion of subjects achieving at least a 2-point improvement in the HDSM-Ax1 score from baseline to EOT2 was 49.3% (n=173). Additionally the change in GSP3 from baseline to EOT was -129.5mg. Overall, 82% of patients who were randomized to the dose in the study completed the full six weeks of treatment. Five (2.9%) subjects who received the dose discontinued due to a TEAE. No treatment-related Serious Adverse Events (SAEs) were reported. Noted October 7, 2021.",1
NVO,Prostate cancer (CRPC),Phase 1,2021-10-07 00:00:00,"Phase 1 initial preliminary results reported include data as of Sept. 1, 2021, from eight men enrolled in the trial. The dose was administered in 28-day cycles, with 21 days of dosing followed by seven days of no dosing. (3/8) patients remain on study; (5/8) patients left the study (4 due to disease progression and 1 withdrawal of consent).",0
SRPT,Limb-girdle muscular dystrophy type 2E (LGMD2E),Phase 1/2,2021-10-11 00:00:00,"Results from most recent study found that treated participants (n=4, ages 4 to 7 years) improved 8.6 points on the NSAA compared to a matched natural history cohort 3 years after treatment- noted October 11, 2021.",1
CRSP,CD19+ B-cell malignancies,Phase 1,2021-10-12 00:00:00,"Phase 1 data demonstrated 58% overall response rate (ORR) and 38% complete response (CR) rate with a single dose at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis. Durable responses achieved with six-month CR rate of 21% and longest response on-going at over 18 months after initial infusion, noted October 12, 2021.",1
OYST,Dry eye disease,Approved,2021-10-18 00:00:00,"Approved October 18, 2021.",1
AVRO,Fabry disease,Phase 2,2021-10-19 00:00:00,"Phase 2 safety data noted that no adverse events (AEs) or serious adverse events (SAEs) were reported, October 19, 2021.",0
BIIB,X-linked Retinitis Pigmentosa,Phase 2/3,2021-10-20 00:00:00,"Phase 2/3 trial discontinued noted October 20, 2021.",-1
REGN,Asthma - 6-11 year-olds,Approved,2021-10-20 00:00:00,"Approved October 20, 2021.",1
AKTX,Atopic keratoconjunctivitis,Phase 1/2,2021-10-25 00:00:00,"Phase 1/2 early clinical data demonstrated a clear dose response effect. The optimal dose showed a greater reduction in inflammation score than cyclosporin and dexamethasone compared to control at day 10 (79% [nomacopan], 41% [cyclosporin], and 73% [dexamethasone]), noted October 25, 2021.",1
ERYP,Pancreatic cancer,Phase 3,2021-10-25 00:00:00,"Phase 3 trial did not meet its primary endpoint of overall survival, noted October 25, 2021.",1
CLSD,Macular edema associated with uveitis,Approved,2021-10-25 00:00:00,"Approved October 25, 2021.",1
MYOV,Contraception,Phase 3,2021-10-26 00:00:00,"Phase 3 trial resumed following clinical hold August 2021 after study protocol amendments, noted October 26, 2021.",0
ELTX,Acute kidney injury (AKI) / Delayed Graft Function,Phase 3,2021-10-26 00:00:00,"Phase 3 trial did not met the primary endpoint, noted October 26, 2021.",0
NVS,Chronic spontaneous urticaria (CSU),Phase 2,2021-10-27 00:00:00,"Phase 2 trial met primary endpoint, noted October 27, 2021.",0
RFL,Acute myeloid leukemia (AML),Phase 3,2021-10-28 00:00:00,"Phase 3 trial to be stopped due to lack of efficacy based on recommendation from independent data monitoring committee, noted October 28, 2021.",-1
PTGX,Crohn's disease,Phase 2,2021-11-03 00:00:00,"Phase 2 trial and candidate development has been stopped, noted November 3, 2021.",-1
BMY,Psoriatic arthritis,Phase 2,2021-11-03 00:00:00,"Phase 2 reported suppressed blood biomarkers of the IL-23/IL-17 and IFN-1 pathways and key markers of joint damage. There were no clinically meaningful changes in mean levels of serum cholesterol, creatinine, neutrophils and platelets over time with deucravacitinib treatment, noted November 3, 2021.",1
ATRA,Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT),Phase 3,2021-11-04 00:00:00,"Phase 3 data reported a 50% objective response rate (ORR), noted November 4, 2021.",0
ETON,Seizures/migraine,Approved,2021-11-08 00:00:00,"FDA Approval November 8, 2021.",1
RVNC,Cervical dystonia,Phase 3,2021-11-09 00:00:00,"Open label data reported a median duration of effect ranging from 19.9 weeks to 26.0 weeks across doses. The most common treatment-related adverse events were muscular weakness (4.9%), dysphagia (4.2%) and injection site pain (2.7%), noted November 9, 2021.",1
ALXO,Head and neck squamous cell carcinoma (HNSCC),Phase 2,2021-11-09 00:00:00,"Phase 2 clinical data showed that patients with 1L HNSCC who have not received prior treatment for their advanced disease (n=13), the dose demonstrates an initial ORR of 38.5% with a 12-month OS rate of 87.5% and mOS not reached in combination with pembrolizumab + 5FU + platinum. These results compare favorably with benchmark survival data from standard pembrolizumab + chemotherapy, noted November 9, 2021.",1
ASMB,Hepatitis B virus (HBV),Phase 2,2021-11-12 00:00:00,"Phase 2 data reported that treatment led to a deeper level of viral suppression as measured by pgRNA and HBV DNA levels, noted November 12, 2021.",1
IONS,Hypertriglyceridemia,Phase 3,2021-11-13 00:00:00,"Phase 3 data reported a significant reduction in total TRL particle (TRLP) concentration by 51%. Total LDL particle (LDLP) concentration was not changed, small LDLP numerically decreased by 39% while medium LDLP increased by 187%, noted November 13, 2021.",1
PHGE,Acne,Phase 2,2021-11-15 00:00:00,"Program to be discontinued to focus resources on CF and AD programs, noted November 15, 2021.",-1
BMY,Venous thromboembolism (VTE) prevention post total knee replacement (TKR) surgery,Phase 2,2021-11-15 00:00:00,"Phase 2 trial met both primary endpoints; the dose response for efficacy was significant, and the 12% rate of VTE was significantly lower than the prespecified benchmark rate of 30%, noted November 15, 2021.",0
MRK,Renal cell carcinoma (RCC),Approved,2021-11-18 00:00:00,"Approved November 18, 2021.",1
TAK,Cytomegalovirus (CMV),Approved,2021-11-23 00:00:00,"Approved November 23, 2021.",1
AADI,PEComa​,Approved,2021-11-23 00:00:00,"Approved November 23, 2021.",1
BLCM,HER2+ Solid Tumors,Phase 1/2,2021-12-06 00:00:00,"Phase 1/2 initial data reported no dose-limiting toxicities with other Grade 3+ treatment-emergent adverse events being neutropenia, leukopenia, and anemia, noted December 6, 2021.",1
GHRS,Treatment-Resistant Depression (TRD),Phase 2,2021-12-06 00:00:00,"Phase 2 trial met primary and secondary endpoints, noted December 6, 2021.",0
BCTX,Breast cancer,Phase 1/2,2021-12-09 00:00:00,"Phase 1/2a data reported that the control rate was 25% and 30% for the monotherapy studies and 33% for the combination study, noted December 9, 2021.",0
IMVIQ,Platinum Resistant Ovarian Cancer,Phase 2,2021-12-09 00:00:00,"Phase 2 data reported increases in both T and B cell immune infiltration, and more prominent antigen-specific humoral responses, noted December 9, 2021.",0
JAGX,Cancer related diarrhea (CRD),Phase 2,2021-12-10 00:00:00,"Phase 2 results reported that CID occurred significantly less (23%) in the crofelemer group during cycle 1 and crofelemer patients were 1.8 times more likely than control patients to have their diarrhea resolved, noted December 10, 2021.",0
NEXI,Multiple Myeloma,Phase 1/2,2021-12-12 00:00:00,"Phase 1/2 data reported that treatment is well-tolerated without dose-limiting toxicities, noted December 12, 2021.",1
NKTR,1L Non-small cell lung cancer (NSCLC),Phase 2,2021-12-13 00:00:00,"Phase 2 data reported an overall response rate (ORR) of 17%, including 2 complete responses (CR) in the highest PD-L1 status cohort, noted December 13, 2021.",0
KURA,Relapsed or refractory peripheral T-cell lymphoma,Phase 2,2021-12-13 00:00:00,"Phase 2 final results reported an overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, noted December 13, 2021.",0
GMAB,Non-Hodgkin Lymphoma (NHL),Phase 1/2,2021-12-14 00:00:00,"Phase 1/2 data reported that 25% of patients reported Grade 4 Neutropenia, with a 73% CMR and a 27% PMR, noted December 14, 2021.",0
MGTA,Multiple Myeloma,Phase 2,2021-12-14 00:00:00,"Phase 2 investigator-initiated clinical trial data confirmed previously reported positive topline clinical data where it achieved the primary endpoint for collection of hematopoietic stem cells (HSCs), was well-tolerated and mobilized HSCs which were able to successfully engraft with positive 100-day outcomes.",1
ABBV,Psoriatic arthritis,Approved,2021-12-15 00:00:00,"Approved December 15, 2021.",1
EGRX,Increase blood pressure in adults,Approved,2021-12-15 00:00:00,"Approved December 15, 2021.",1
CALT,IgA nephropathy,Approved,2021-12-15 00:00:00,"Approved December 15, 2021.",1
ZLAB,Myasthenia gravis (MG),Approved,2021-12-17 00:00:00,"Approved December 17, 2021.",1
AMGN,Plaque psoriasis,Approved,2021-12-20 00:00:00,"Approved December 20, 2021.",1
VALN,Chikungunya Vaccine,Phase 3,2021-12-21 00:00:00,"Phase 3 trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent immune responses measured by neutralizing antibody titer GMT ratios on Day 29 after vaccination.",1
GSK,HIV,Approved,2021-12-21 00:00:00,"Approved December 21, 2021.",1
NVS,Hypercholesterolemia,Approved,2021-12-22 00:00:00,"Approved December 22, 2021.",1
FATE,"B-Cell Chronic Lymphoma, chronic lymphocytic leukemia",Phase 1,2021-12-31 00:00:00,"Phase 1 interim data released August 19, 2021. 10/14 patients (71%) achieved an objective response; 7/14 (50%) complete responses. Phase 1 data reported 5 of 6 patients achieve objective response with 4 with a complete response, noted December 13, 2021.",1
HEPA,NASH and Liver Cancer,Phase 2a,2022-01-08 00:00:00,"Phase 2a data reported that treatment was well-tolorated with ALT decreased in 50%, 67%, and 87% of the subjects in the placebo, 75 mg, and 225 mg cohorts, respectively, noted January 8, 2022.",1
PFE,Pneumococcal + Covid-19 vaccine dual administration in 65<,Phase 3,2022-01-12 00:00:00,"Phase 3 top-line results noted that responses for all 20 serotypes and to the covid-19 vaccine were similar, with a safety profile similar to the booster dose, noted January 12, 2022.",0
PFE,Atopic Dermatitis,Approved,2022-01-14 00:00:00,"Approved January 14, 2022.",1
ARCT,COVID-19 variant vaccine,Phase 1/2,2022-01-24 00:00:00,"Additional Phase 1/2 data reported neutralization against several variants of concern after day 15 and 29, noted January 24, 2022.",0
LLY,Primary Sjogren's Syndrome,Phase 2,2022-01-27 00:00:00,"Phase 2 study withdrawn noted January 27, 2022.",0
RHHBY,Diabetic Macular Edema,Approved,2022-01-28 00:00:00,"FDA Approval announced January 28, 2022.",1
GSK,HIV,Approved,2022-02-01 00:00:00,"Approved February 1, 2022.",1
VNDA,Gastroparesis,Phase 3,2022-02-04 00:00:00,"Phase 3 data reported that the trial did not meet its primary endpoint, noted February 4, 2022.",1
MRK,Metastatic non-small cell lung cancer (NSCLC),Phase 3,2022-02-08 00:00:00,"Phase 3 trial did not meet primary endpoints of overall survival, safety profile was consistent with that observed in the overall JAVELIN clinical development program, noted February 8, 2022.",1
AGIO,Pyruvate kinase deficiency,Approved,2022-02-17 00:00:00,"Approved February 17, 2022.",1
ABBV,Crohn's disease,Phase 3,2022-02-24 00:00:00,"Phase 3 trial met primary endpoint, noted February 24, 2022.",0
LEGN,Multiple myeloma,Approved,2022-02-28 00:00:00,"Approved February 28, 2022.",1
GILD,HIV,CRL,2022-03-01 00:00:00,"CRL announced March 1, 2022.",0
MRK,BRCAm HER2-negative breast cancer,Approved,2022-03-11 00:00:00,"Approved March 11, 2022.",1
BMY,Melanoma,Approved,2022-03-18 00:00:00,"Approved March 18, 2022.",1
ALNA,Enteric Hyperoxaluria,Phase 3,2022-03-18 00:00:00,"Phase 3 interim analysis due late 1Q 2022. Based on the results by an independent DSMB has recommended that the trial size be increased from the maximum allowed number of 400 subjects under the pre-specified rules. However, even with this maximum recommended sample size increase, the power to detect an effect vs. placebo would still be less than 80% based on the available data. Based upon this recommendation, the company has decided to terminate the study and plans to promptly initiate the process of closing the study.",-1
AMGN,Palmoplantar pustulosis for Japanese patients,Phase 2,2022-03-27 00:00:00,"Phase 2 data APR demonstrated shorter median time to PPPASI-50 response than PBO. The most common adverse events included gastrointestinal events and headache, noted March 27, 2022.",1
ALZN,Mild to Moderate Dementia of the Alzheimer's Type,Phase 1/2,2022-03-28 00:00:00,"Phase 1 results reported that treatment was safe and well-tolerated and salicylate exposures were within safe limits, noted March 28, 2022.",1
REVB,H3N2 Influenza,Phase 2b,2022-03-30 00:00:00,"Phase 2b trial did not meet primary efficacy endpoint, noted March 30, 2022.",1
AMGN,Heart failure with reduced ejection fraction (HFrEF),Phase 3,2022-04-03 00:00:00,"Phase 3 results reported that there was no change in pVO2 in patients treated with omecamtiv mecarbil versus placebo, noted April 3, 2022.",1
AZN,Dyslipidaemia,Phase 2b,2022-04-04 00:00:00,"Phase 2b study met its primary and secondary endpoints; ION449 was generally well tolerated, noted April 4, 2022",1
AIM,Metastatic triple-negative breast cancer,Phase 1/2,2022-04-11 00:00:00,"Phase 1 data presented at AACR reported that trial met primary endpoint, noted April 11, 2022.",1
BMY,Non-small-cell lung cancer (NSCLC) and solid tumors,Phase 1/2,2022-04-12 00:00:00,"Phase 1/2 top-line data reported that in the ROS1-positive TKI-naïve advanced NSCLC population the cORR was 79%, with 4 patients receiving a complete response, and 52 having a partial response. With DOR ranging from 1.4+ to 35.1+ months and PFS ranging from 0+ to 40.4+ months, noted April 12, 2022.",0
SNY,Breast Cancer,Phase 2,2022-04-28 00:00:00,"Phase 2 pivotal trial did not meet it primary endpoint, noted April 28, 2022.",1
BMY,Hypertrophic cardiomyopathy (HCM),Approved,2022-04-28 00:00:00,"Approved April 28, 2022.",1
FWBI,COVID-19-related gastrointestinal (GI) infections,Phase 2,2022-04-29 00:00:00,"Phase 2 top-line data reported that trial did not meet its primary endpoint, noted April 29, 2022.",1
ABBV,Active Ankylosing Spondylitis,Approved,2022-04-29 00:00:00,"Approved April 29, 2022.",1
PALI,Improvement in bowel function following cardiovascular surgery,Phase 2,2022-05-02 00:00:00,"Phase 2 trial met primary endpoint, noted May 2, 2022.",0
AZN,Second line HER2+ breast cancer,Approved,2022-05-05 00:00:00,"Approved May 5, 2022.",1
RCKT,Leukocyte Adhesion Deficiency-I (LAD-I),Phase 1/2,2022-05-19 00:00:00,"Phase 2 top-line data reported a 100% survival rate at 12-months post-infusion, with statistically significant reduction in the rate of all-cause hospitalizations and severe infections, noted May 19, 2022.",1
AMPH,Radionuclide myocardial perfusion imaging (MPI),Approved,2022-05-24 00:00:00,"Approved May 24, 2022.",1
NRXP,COVID-19,Phase 3,2022-05-25 00:00:00,"Phase 3 DSMB review requested that randomization to aviptadil be stopped due to not meeting the futility guidelines, noted May 25, 2022.",1
ADAP,Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS),Phase 1,2022-05-26 00:00:00,"Phase 1 data released May 26, 2022. The overall response rate was 36% in heavily pre-treated patients across both types of sarcomas (41% in synovial sarcoma and 10% for MRCLS), with a median duration of response of 52 weeks. As reported last year, the pivotal trial SPEARHEAD-1 met its primary endpoint for efficacy and the benefit:risk profile of afami-cel has been favorable with mainly low-grade cytokine release syndrome and tolerable/reversible hematologic toxicities.",1
EXEL,Recurrent or metastatic head and neck cancer,Phase 2,2022-05-26 00:00:00,"Phase 2 data released on May 26, 2022. The trial met its primary endpoint of objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at 54%. The overall clinical benefit rate was 91%. At a median follow-up of 10.6 months, the one-year progression-free survival rate was 54.0%, and median progression-free survival was 14.6 months. The one-year overall survival (OS) rate was 68.4%. For the 17 patients with a PD-L1 combined positive score (CPS) under 20, the one-year OS rate was 54.9%. For the 17 patients with a CPS score of 20 or more, the one-year OS rate was 83.6%.",1
HOOK,Treatment-refractory HPV16+ cancers,Phase 1/2,2022-05-26 00:00:00,"Phase 1/2 data from abstract reported that treatment was well-tolerated with adverse events being mild or moderate, noted May 26, 2022.",1
EQRX,1L metastatic non-small cell lung cancer (NSCLC),Phase 3,2022-05-26 00:00:00,"Phase 3 data reported that the median OS was 25.4 months versus 16.9 months in placebo, noted May 26, 2022.",0
ZYME,HER2-positive breast cancer,Phase 1/2,2022-05-26 00:00:00,"Phase 1b/2 data released in abstract reported that the cORR was 90.5% and the six-month progression-free survival rate was 95.2%, noted May 26, 2022.",0
ETON,"Lennox-Gastaut syndrome, epilepsy",CRL,2022-05-27 00:00:00,"CRL announced May 27, 2022.",0
ELDN,Amyotrophic Lateral Sclerosis,Phase 2a,2022-05-31 00:00:00,"Phase 2a topline data showed that treatment met the primary endpoints of safety and tolerability. Adverse events were equally distributed across dose levels, noted May 31, 2022.",1
NVO,Type 2 diabetes,Phase 3,2022-06-03 00:00:00,"Phase 3a trial met primary endpoint, noted June 3, 2022.",0
KZIA,Glioblastoma multiforme,Phase 2,2022-06-03 00:00:00,"Phase 2 final data presented at ASCO reported that the median overall survival (OS) in the intent-to-treat (ITT) population was 15.7 months, compared to 12.7 months which was historically reported with temozolomide in this patient group. Median progression-free survival (PFS) in the ITT population was 8.6 months, noted June 3, 2022.",1
NVCR,Gastric cancer,Phase 2,2022-06-03 00:00:00,"Phase 2 data reported a confirmed objective response rate of 50%, with a 10.3 month duration of response and 72% one-year survival rate, noted June 3, 2022.",0
MEIP,Relapsed/refractory Follicular Lymphoma (FL) Non Hodgkin Lymphoma,Phase 2,2022-06-04 00:00:00,"Phase 2 top-line data presented at ASCO 22 reported a 70.3% objective response rate and that 35.2% achieved a complete response. 87.5% of responses achieved in first two cycles of therapy, 75% of CRs in first four cycles, 9.9% of patients discontinued the trial due to drug related adverse events, follow-up time for response was 8.4 months, and 83% reported grade 3 AE of special interest in cycles 1-3.",1
LLY,Type 2 diabetes,Phase 3,2022-06-04 00:00:00,Phase 3 data results presented at ADA's 82nd Scientific Sessions® and simultaneously published in the New England Journal of Medicine demonstrate A1C reductions of up to 1.5% for Trulicity compared to placebo in this underserved population.,1
CLVS,Ovarian Cancer - First-line maintenance treatment,Phase 3,2022-06-06 00:00:00,"Additional Phase 3 data reported that median PFS for the HRD-positive patient population treated with rucaparib was 28.7 months, noted June 6, 2022.",1
GILD,Refractory Large B-cell Lymphoma (R-LBCL),Phase 2,2022-06-06 00:00:00,"Phase 2 data presented at ASCO reported a CR rate of 65% and ORR of 88%. With a median follow-up of 17 mo, 65% of the patients had ongoing response, with 57% ongoing in CR, noted June 6, 2022.",1
IMVIQ,Ovarian Cancer,Phase 1/2,2022-06-06 00:00:00,"Results from Phase 1 and Phase 2 expansion cohort presented at ASCO reported that G3/G2 immune-related AE and injection site reactions were observed in 1/1 and 1/3 pts treated at DL1, and in 1/0 and 2/2 pts at DL2, respectively. At Phase 1, one patient with MSI-High clear cell subtype had an ongoing CR after 26 months of follow-up, 2 patients had PR and 6 SD. There were 1 PR and 3 SD on P2EC, of which 1 and 2, respectively, achieved response greater than 12 weeks, noted June 6, 2022.",1
GILD,Refractory metastatic triple-negative breast cancer (TNBC),Phase 3,2022-06-06 00:00:00,"Phase 3 final results reported that Trodelvy improved median progression-free survival versus physicians' choice of chemotherapy to 4.8 vs. 1.7 months and extended median overall survival (OS) by almost five months, noted June 6, 2022.",1
CLVS,Endometrial Cancer,Phase 2,2022-06-07 00:00:00,"Phase 2 data reported that 23 subjects had clinical benefit, with 1 (4%) with CR, 9 (39%) with PR, and 13 (57%) with stable disease as best response, noted June 7, 2022.",0
TALS,COVID-19 in living donor kidney transplant (LDKT) patients,Phase 2,2022-06-07 00:00:00,"Additional Phase 2 data presented at ATC reported that none of these 18 patients lost chimerism as a result of their COVID-19 vaccination, noted June 7, 2022.",1
TAK,Dengue Vaccine,Phase 3,2022-06-09 00:00:00,"Phase 3 data reported that treatment prevented 84% of hospitalizations and 61% of symptomatic dengue illness overall, with identified safety risks, noted June 9, 2022.",1
RYTM,Bardet-Biedl Syndrome,Approved,2022-06-16 00:00:00,"Approved June 16, 2022.",1
PFE,COVID-19 vaccine,Approved,2022-06-17 00:00:00,"EUA approval for children 4 years - 6 months, noted June 17, 2022.",1
MRNA,Bivalent booster COVID-19 vaccine,Phase 2/3,2022-06-22 00:00:00,"Phase 2/3 trial data reported that neutralizing titers against BA.4/BA.5 were approximately 3-fold lower than previously reported neutralizing titers against BA.1. One month after an mRNA-1273.214 booster, neutralizing geometric mean titers (GMT) against BA.4/BA.5 were 941 (95% CI: 826, 1071) in all participants, and 727 (95% CI: 633, 836) in seronegative participants, noted June 22, 2022.",0
NVS,Solid tumors in adult and pediatric patients,Approved,2022-06-22 00:00:00,"Approved June 22, 2022.",1
ANIP,Tranxene generic,Approved,2022-06-22 00:00:00,"Approved June 22, 2022.",1
AURA,Indeterminate lesions (ILs) and choroidal melanoma (CM),Phase 1/2,2022-06-22 00:00:00,"Phase 1b/2 reported results from retrospective matched case control study, treatment achieved statistically significant vision preservation compared current standard of care, noted June 22, 2022.",1
ARWR,AATD-associated liver disease,Phase 2,2022-06-27 00:00:00,"Phase 2 data showed noted a Fibrosis regression observed in 58% (7/12) of patients receiving 200 mg, a median reduction of 83% of Z-AAT accumulation in the liver and a reduction of 69% in histologic globule burden",1
SPRO,Complicated urinary tract infections (cUTI),CRL,2022-06-27 00:00:00,"CRL announced June 27, 2022.",0
IONS,Chronic hepatitis B virus (CHB),Phase 2b,2022-06-27 00:00:00,"Phase 2b data readout reported that up to 68% of patients on NA therapy and up to 65% of patients not on NA achieved HBsAg <100 IU/mL at the end of treatment, noted June 27, 2022.",1
ALDX,Dry eye disease,Phase 3,2022-07-12 00:00:00,"Phase 3 crossover results reported that met both primary endpoints, noted July 12, 2022.",0
NVAX,COVID-19 vaccine,Approved,2022-07-13 00:00:00,"Emergency Use Authorization (EUA) granted July 13, 2022.",0
RARE,Angelman Syndrome,Phase 1/2,2022-07-18 00:00:00,"Phase 1/2 UK data reported that treatment displayed a meaningful improvement in clinical disease and an acceptable safety profile, noted July 18, 2022.",1
ETON,Epilepsy,Approved,2022-07-18 00:00:00,"Approved July 18, 2022.",1
MRK,Head and neck squamous cell carcinoma (HNSCC),Phase 3,2022-07-20 00:00:00,"Phase 3 trial did not meet primary endpoint, noted June 20, 2022.",1
VTGN,Social Anxiety Disorder (SAD),Phase 3,2022-07-22 00:00:00,"Phase 3 trial did not meet primary endpoint, noted July 22, 2022.",1
MYOV,Endometriosis,Phase 3,2022-07-28 00:00:00,"Phase 3 data reported that trials met both co-primary endpoints with 75% of women in the relugolix combination therapy group in both studies achieving a clinically meaningful reduction in dysmenorrhea compared with 27% and 30% of women in the placebo groups at Week 24, respectively, noted July 28, 2022.",1
IPHA,Head and neck squamous cell carcinoma of the head and neck (SCCHN),Phase 3,2022-08-01 00:00:00,"Phase 3 trial did not meet the futility interim analysis, noted August 1, 2022.",1
RHHBY,Autosomal Dominant Alzheimer's Disease (ADAD,Phase 3,2022-08-02 00:00:00,"Additional Phase 3 data reported that cognitive test scores of API ADAD composite 22.9%, FCSRT 19.9% and RBANS total score 43.8%, noted August 2, 2022.",0
ABBV,Jawline definition,Approved,2022-08-03 00:00:00,"Approved August 3, 2022.",1
MRK,Metastatic castration-resistant prostate cancer (mCRPC),Phase 3,2022-08-03 00:00:00,"Phase 3 trial results were not statistically significant, noted August 3, 2022.",0
NBIX,Essential Tremor,Phase 2,2022-08-04 00:00:00,"Phase 2 trial did not meet primary endpoints, noted August 4, 2022.",1
ACAD,Alzheimer’s disease psychosis (ADP),CRL,2022-08-05 00:00:00,"CRL announced August 5, 2022.",0
AZN,HER low breast cancer,Approved,2022-08-05 00:00:00,"Approved August 5, 2022.",1
MYOV,Endometriosis-associated pain,Approved,2022-08-05 00:00:00,"Approved August 5, 2022.",1
CYAD,Colorectal cancer,Phase 1,2022-08-05 00:00:00,"Phase 1 preliminary data noted 2/15 partial responses from the dose-escalation segment. Median progression-free survival (mPFS) and median overall survival (mOS) was 3.9 months and 10.6 months, respectively.",0
ALNA,Gout in chronic kidney disease (CKD),Phase 2a,2022-08-10 00:00:00,"Cohort A and B initial data reported that the data was not statistically significant, noted August 10, 2022.",0
FSTX,Head and neck cancer,Phase 2,2022-08-11 00:00:00,"Phase 2 data reported that treatment was well tolerated and cleared the pre-determined futility, noted August 11, 2022.",1
VTYX,Plaque psoriasis,Phase 1,2022-08-15 00:00:00,"Phase 1 data reported that treatment was well-tolerated with a dose-dependent increase in expsoure and target coverage, noted August 15, 2022.",1
BLUE,β-Thalassemia,Approved,2022-08-17 00:00:00,"Approved August 17, 2022.",1
AXSM,Major Depressive Disorder,Approved,2022-08-19 00:00:00,"FDA Approved on August 19, 2022.",1
AMGN,Paroxysmal nocturnal hemoglobinuria (PNH),Phase 3,2022-08-23 00:00:00,"Phase 3 trial met its primary endpoint, noted August 23, 2022.",0
JNJ,Pediatric Chronic Graft-Versus-Host Disease,Approved,2022-08-24 00:00:00,"Approved August 24, 2022.",1
INCY,Myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement,Approved,2022-08-26 00:00:00,"Approved August 26, 2022.",1
BYSI,Multiple Myeloma,Phase 2,2022-08-29 00:00:00,"Phase 2 data reported that the median white blood count (WBC) on Day 0, 1 and 2 was 7.6. Six patients had fever at median of eight days post AHCT. Five patients with engraftment syndrome were treated with steroids, and there was one patient with non-engraftment-related neutropenic fever, noted August 29, 2022.",1
JNCE,Second-line non-small cell lung cancer (NSCLC) patients,Phase 2,2022-08-30 00:00:00,"Phase 2 trial did not meet its primary endpoint, noted August 30, 2022.",1
AMYT,Maintenance treatment of adult acromegaly,Phase 3,2022-09-07 00:00:00,"Additional Phase 3 data reported that no new or increased safety signals were identified with a shorter time to initiation of Mycapssa, noted September 7, 2022.",0
TAK,Colorectal cancer,Phase 3,2022-09-08 00:00:00,"Phase 3 data demonstrated that treatment reduced the risk of death by 34% in metastatic colorectal cancer , and Increased disease control with risk of disease progression or death reduced by 68%, noted September 8, 2022",1
EXEL,Renal Cell Carcinoma (RCC),Phase 3,2022-09-08 00:00:00,"Phase 3 data presented at ESMO reported that the median PFS was not reached for the triple combination and was 11.3 months for the combination of nivolumab and ipilimumab. Objective response rates in the PFS intent-to-treat population was 43% and 36%, respectively, noted September 8, 2022.",1
ARQT,Seborrheic dermatitis,Phase 3,2022-09-09 00:00:00,"Additional Phase 3 data presented at EADV reported that more than 60% of patients treated with roflumilast foam achieved an itch response at Week 8, noted September 9, 2022.",1
AMGN,Plaque psoriasis in pediatric patients,Phase 3,2022-09-09 00:00:00,"Phase 3 primary endpoint was met, noted September 8, 2022.",0
NKTR,Solid Tumors,Phase 1b,2022-09-10 00:00:00,"Phase 1b data presented at ESMO demonstrated preliminary clinical activity similar to that observed with cabozantinib in Phase 1 across a range of solid tumors and dose levels, with a manageable safety profile, noted September 10, 2022.",1
BMY,Solid Tumors,Phase 1b,2022-09-10 00:00:00,"Phase 1b data presented at ESMO demonstrated preliminary clinical activity similar to that observed with cabozantinib in Phase 1 across a range of solid tumors and dose levels, with a manageable safety profile, noted September 10, 2022.",1
GRTS,Solid tumors,Phase 1/2,2022-09-12 00:00:00,"Phase 2 portion data from Phase 1/2 trial presented at ESMO demonstrated early evidence of efficacy with a 39% molecular response rate in evaluable patients with late-line microsatellite-stable colorectal cancer (MSS-CRC) and non-small cell lung cancer (NSCLC). Data support moving trial into earlier lines of treatment, noted September 12, 2022.",1
GRTS,Non-small cell lung cancer (NSCLC),Phase 2,2022-09-12 00:00:00,"Phase 2 data presented at ESMO demonstrated early evidence of efficacy with a 39% molecular response rate in evaluable patients, noted September 12, 2022.",1
TRVI,Chronic cough - Idiopathic pulmonary fibrosis (IPF),Phase 2,2022-09-19 00:00:00,"Phase 2 full data reported that trial met primary endpoint, noted September 19, 2022.",0
ZLDPF,Pediatric Congenital hyperinsulinism (CHI),Phase 3,2022-09-19 00:00:00,"Phase 3 trial additional data showed that treatment significantly reduced the requirement for intravenous (IV) glucose to maintain glycemia in neonates and infants with CHI and reduced glucose requirements to levels that potentially allow for discontinuation of IV glucose support, noted September 19, 2022.",1
PCRX,Lower extremity nerve block,Phase 3,2022-09-21 00:00:00,"Phase 3 trial data achieved the study's primary endpoint by demonstrating a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine HCl, noted September 21, 2022.",1
ABVC,Attention Deficit Hyperactivity Disorder (ADHD),Phase 2a,2022-09-23 00:00:00,"Part 1 of Phase 2 study found that the active ingredient of ABV-1505, PDC-1421, was safe, well-tolerated and efficacious during the treatment and follow-up period with six adult patients, noted September 23, 2022.",1
IMGN,Ovarian cancer,Phase 1/2,2022-09-29 00:00:00,"Phase 1/2 data reported an ORR of 44%, a median DOR of 11.8 months, and median PFS of 8.2 months, noted September 29, 2022.",0
AMLX,Amyotrophic lateral sclerosis (ALS),Approved,2022-09-29 00:00:00,"Approved September 29, 2022.",1
GRTS,Non-small cell lung cancer (NSCLC) and colorectal cancer (CRC),Phase 2,2022-09-30 00:00:00,"Phase 2 initial data presented at ESMO noted a 39% molecular response rate (MRR), noted September 2022.",1
KALV,Hereditary angioedema (HAE),Phase 2,2022-10-04 00:00:00,Phase 2 trial has been terminated based on the observation of liver enzyme (ALT/AST) elevations in multiple patients in all treatment groups of the trial and to prioritize the development of the KONFIDENT Phase 3 trial.,1
ANAB,Non-squamous non-small cell lung cancer (NSCLC),Phase 2,2022-10-05 00:00:00,"Phase 2 trial met primary endpoint, noted October 5, 2022.",0
ORMP,COVID-19 vaccine,Phase 1,2022-10-07 00:00:00,"Phase 1 preliminary results reported a significant antibody response (2-6 fold over baseline) and no safety issues observed, noted October 7, 2022.",1
EVFM,Chlamydia and gonorrhea,Phase 3,2022-10-12 00:00:00,"Phase 3 trial did not meet its primary endpoint, noted October 12, 2022.",1
SMMT,C. difficile infection (CDI),Phase 3,2022-10-20 00:00:00,"Phase 3 trial results reported that treatment was numerically higher sustained clinical response rate (73.0% vs 70.7%) than vancomycin, but did not achieve the pre-specified superiority endpoint, noted October 20, 2022.",1
MTNB,Cryptococcal meningitis,Phase 1/2,2022-10-21 00:00:00,"Phase 1/2 cohort 4 data reported that CSF yeast clearance rate exceeded the prespecified primary endpoint, with an interim survival currently 90%, while the survival rate at Week 2 was 95%, noted October 21, 2022.",0
MIRM,Progressive Familial Intrahepatic Cholestasis (PFIC),Phase 3,2022-10-24 00:00:00,"Phase 3 top-line data reported that trial met primary endpoint, noted October 24, 2022.",0
AZN,Eosinophilic Esophagitis,Phase 3,2022-10-25 00:00:00,"Phase 3 data reported that trial did not meet one of the two dual-primary endpoints, noted October 25, 2022.",1
ABUS,Hepatitis B virus (HBV),Phase 2,2022-11-01 00:00:00,"Phase 2 preliminary data from 65 patients randomized to receive AB-729+VBR+NA (n=32), AB-729+NA (n=17) or VBR+NA (n=16) for 48 weeks showed that adding VBR to AB-729+NA does not result in greater on-treatment improvements in markers of HBV infection as compared to AB-729+NA alone, noted November 1, 2022.",1
DNLI,Frontotemporal dementia (FTD) caused by mutations in the granulin gene (GRN),Phase 1/2,2022-11-01 00:00:00,"Phase 1/2 part A interim results showed that single doses of treatment result in substantial increases in CSF progranulin levels suggesting brain delivery of DNL593 was achieved and has the potential to address progranulin deficiency, noted November 1, 2022.",1
KDNY,Chronic kidney disease,Phase 2,2022-11-03 00:00:00,"Interim data reported that of the 20 patients enrolled, ten patients remained on study, nine patients completed 52 weeks of treatment and one patient discontinued after 13 weeks of treatment due to a headache. Treatment demonstrated mean reductions in 24-hour urine protein creatinine ratio (UPCR) of 38.1% at six weeks of treatment, 48.3% at 12 weeks of treatment and 54.7% at 24 weeks of treatment, noted November 3, 2022.",1
FATE,Acute Myelogenous Leukemia / B-cell Lymphoma,Phase 1,2022-11-03 00:00:00,"Phase 1 data reported an 80% objective response rate for CAR T Naive versus 38% for prior CAR T patients, noted December 13, 2021. Received RMAT designation November 3, 2022.",0
IONS,End-stage renal disease (ESRD),Phase 2b,2022-11-04 00:00:00,"Additional Phase 2b data reported that treatment also achieved dose-dependent and sustained median reductions in steady-state FXI levels of 53.1%, 72.2% and 86.6% in the 40 mg, 80 mg, and 120 mg doses of fesomersen, respectively, administered once every 4 weeks, noted November 4, 2022.",1
CGEN,Ovarian Cancer,Phase 1,2022-11-07 00:00:00,"Preliminary Phase 1 data reported a 12% ORR in 3L+ MSS-CRC patients with liver metastases, noted November 7, 2022.",0
NXTC,Solid tumors,Phase 1,2022-11-07 00:00:00,"Phase 1 data reported that treatment is safe and well-tolerated with early signs of disease control in patients with advanced tumors, noted November 7, 2022.",1
CARA,Pruritus associated primary biliary cholangitis (PBC),Phase 2,2022-11-07 00:00:00,"Phase 2 data reported no unexpected adverse events, noted November 7, 2022.",0
MIRM,"Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome",Phase 2,2022-11-08 00:00:00,"Phase 2 data reported that treatment was well tolerated in infants with ALGS aged <1 year, with body weight of ≥2.5 kg, and TEAEs were mostly grade 1 in severity and unrelated to MRX, noted November 8, 2022.",1
ONCY,"Colorectal and advanced anal cancers, pancreatic cancer",Phase 1/2,2022-11-10 00:00:00,"Phase 1/2 data reported a 69% objective response rate (ORR), noted November 11, 2022.",0
SGEN,Previously untreated high risk classical Hodgkin lymphoma (cHL),Approved,2022-11-10 00:00:00,"Approved November 10, 2022.",1
CVAC,Solid tumors,Phase 1,2022-11-11 00:00:00,"Phase 1 data reported that five out of 30 patients (17%) experienced a partial response and no objective responses were observed in the 10 patients of the single-agent cohort, noted November 11, 2022.",1
ASND,Achondroplasia,Phase 2,2022-11-14 00:00:00,"Phase 2 top-line data reported that trial met primary endpoint, noted November 14, 2022.",0
SYRS,Pancreatic Cancer,Phase 1,2022-11-14 00:00:00,"Phase 1 safety data reported that treatment was generally safe, noted November 14, 2022.",1
HCM,Gastric Cancer,Phase 2,2022-11-14 00:00:00,"Phase 3 trial met primary endpoint regarding progression-free survival. The trial did not meet the the overall survival primary endpoint, noted November 14, 2022.",1
AMGN,Rheumatoid Arthritis,Phase 2,2022-11-14 00:00:00,"Phase 2 data reported that DAZ reduced DAS28-CRP and RF significantly vs. PBO at d113 in all dose regimens, noted November 14, 2022.",1
INTS,Solid tumors,Phase 1/2,2022-11-17 00:00:00,"Phase 1/2 data reported at CTOS reported that patients who had 40% or more of their tumor burden treated with INT230-6, an exploratory analysis showed that overall survival was improved when compared to historical benchmarks, noted November 17, 2022.",1
NBRV,Cystic fibrosis (CF),Phase 1,2022-11-28 00:00:00,"Phase 1 top-line data reported that treatment was well-tolerated, noted November 28, 2022.",1
FMTX,Acute myeloid leukemia,Approved,2022-12-01 00:00:00,"Approved December 1, 2022.",1
XENE,Adult Focal Epilepsy,Phase 2b,2022-12-04 00:00:00,"Additional Phase 2b data reported that seizure freedom for ≥6-month and ≥12-month consecutive durations was achieved in 17.5% and 10.5% of patients, respectively, noted December 4, 2022.",1
VALN,Chikungunya vaccine,Phase 3,2022-12-05 00:00:00,"Phase 3 trial met primary endpoint, noted December 5, 2022.",0
BIVI,Alzheimer's disease,Phase 2,2022-12-05 00:00:00,"Phase 2 final data reported that improvements in QDRS scores were statistically significantly correlated with improvements on the ADCOMS assessment, noted December 2, 2022.",1
BIVI,Alzheimer's disease,Phase 2,2022-12-05 00:00:00,"Additional Phase 2 data reported that 18 of 22 patients with abnormal baseline scans showed improvement in one or more brain regions as seen from advanced functional MRI studies, noted December 5, 2022.",1
VOR,Acute myeloid leukemia (AML),Phase 1/2,2022-12-07 00:00:00,"Phase 1/2a trial data from first patients reported that treatment engrafted normally and blood count was successfully maintained following post-transplant treatment, noted December 7, 2022.",1
MNOV,Non-alcoholic fatty liver disease (NAFLD) with Type 2 Diabetes Mellitus and Hypertriglyceridemia,Phase 2,2022-12-07 00:00:00,"Additional Phase 2 data reported that T2DM group showed a greater reduction in serum triglyceride levels at Week 8 and Mean HDL increase was significantly greater in subjects with T2DM than subjects without T2DM at Week 8, noted December 7, 2022.",1
GTHX,Early-stage triple negative breast cancer (TNBC),Phase 2,2022-12-08 00:00:00,"Phase 2 data reported a trend toward an increased ratio of CD8+ T-cells to Tregs within the tumor microenvironment, indicating trilaciclib may favorably modulate the composition of immune cells to support antitumor immune responses, noted December 8, 2022.",1
AMAM,Breast cancer,Phase 2,2022-12-09 00:00:00,"Phase 2 safety and efficacy data demonstrated a 57.1% confirmed overall response rate (ORR) with 100% disease control rate (DCR), noted December 9, 2022.",1
AZN,Solid tumors,Phase 1,2022-12-09 00:00:00,"Phase 1 data reported that IPH5201 blocks ATP degradation and blocks CD39-mediated degradation of eATP released after chemotherapy treatment, noted December 8, 2022.",1
AZN,"Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer and Non-small Cell Lung Cancer",Phase 1,2022-12-09 00:00:00,"Phase 1 data reported an objective response rate (ORR) of 27% with all patients achieving a partial response and 56% with stable disease, noted December 9, 2022.",1
SLRX,Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML),Phase 1/2,2022-12-12 00:00:00,"Phase 1/2 data presented at ASH reported an ORR of 50% among eight myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), noted December 12, 2022.",1
IMAB,Acute Myeloid Leukemia / Myelodysplastic Syndrome,Phase 2,2022-12-12 00:00:00,"Phase 2 data reported an increased CALR expression in CD33+ blasts after lemzoparlimab and AZA combination treatment and higher immune infiltrates including total, CD91+ macrophages and CD8/Treg ratio in bone marrow at baseline is associated with better clinical response, suggesting the important role of activation of tumor derived pro-phagocytic signal and effector immune cells in the anti-tumor activity mediated by combination treatment, noted December 12, 2022.",1
JAZZ,Sickle Cell Disease-Related Acute Chest Syndrome,Phase 2,2022-12-12 00:00:00,"Phase 2 data reported that among patients who underwent Day 30 CXR or CTA, 87.5% and 92%, respectfully, showed improvement or resolution of pulmonary consolidation, noted December 12, 2022.",1
XNCR,"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, DLBCL",Phase 1,2022-12-12 00:00:00,"Phase 1 data reported an overall response rate (ORR) was 52.0% (13/25), and the complete response rate was 24.0% (6/25), noted December 12, 2022.",0
REGN,Multiple myeloma,Phase 2,2022-12-12 00:00:00,"Phase 2 data reported a 64% response rate, with 45% of responders achieving a very good partial response or better, noted December 12, 2022.",1
PRTC,Solid tumors,Phase 1/2,2022-12-12 00:00:00,"Phase 1/2 data reported no dose limiting toxicities, noted December 12, 2022.",0
AGIO,Thalassemia,Phase 2,2022-12-12 00:00:00,"Phase 2 data reported durable improvements in hemoglobin concentration and markers of hemolysis and ineffective erythropoiesis were observed for up to 72 weeks of treatment in both α- and β-thalassemia patients, noted December 12, 2022.",1
ONCT,Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL),Phase 1/2,2022-12-12 00:00:00,"Phase 1/2 data reported that the ORR of 89% and CR rate of 43% for patients with MCL treated with zilovertamab plus ibrutinib compare favorably to the historical ORR of 66% and CR rate of 20% for ibrutinib monotherapy, noted December 12, 2022,",1
MRTX,Non-small cell lung cancer (NSCLC) with a KRASG12C Mutation,Approved,2022-12-13 00:00:00,"Approved December 13, 2022.",1
BYSI,Docetaxel-induced neutropenia in breast cancer,Phase 2/3,2022-12-13 00:00:00,"Additional data reported that plinabulin was superior vs no-treatment for DIN and hematologic complications, noted December 13, 2022.",1
VIGL,Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP),Phase 1,2022-12-14 00:00:00,"Phase 1 trial achieved favorable safety, tolerability and PK profiles in single ascending dose and multiple ascending dose cohorts. VGL101 achieved dose dependent, robust and durable decreases in CSF sTREM2 demonstrating proof of target engagement further validating its mechanism of action, noted December 14, 2022.",1
SNY,Hidradenitis suppurativa / atopic dermatitis,Phase 1,2022-12-14 00:00:00,"Phase 1 data reported that a 37% mean reduction in EASI in AD and 42% of HS patients has AN Count 0/1/2, noted December 14, 2022.",1
ASMB,Hepatitis B,Phase 1b,2022-12-19 00:00:00,"Phase 1b data reported that in the cohort of 50 mg, six of eight HBV patients on treatment reached lower limit of quantification for HBV DNA by day 21 and patients showed a mean reduction of 3.1 logs in plasma HBV DNA, noted December 19, 2022.",1
AZN,Non-small cell lung cancer (NSCLC),Phase 3,2022-12-19 00:00:00,"Phase 3 trial did not meet primary endpoint, noted December 19, 2022.",1
GTHX,Neoadjuvant breast cancer,Phase 2,2022-12-20 00:00:00,"Phase 2 data reported that oral treatment was associated with less neuropathy and was not associated with an increase in febrile neutropenia, noted December 20, 2022.",1
ATAI,Opioid Use Disorder,Phase 1,2022-12-23 00:00:00,"Additional results from part 2 showed that a single dose was generally well tolerated and was observed to produce analgesic effects on CPT comparable to those seen in Part 1 of this trial, noted December 23, 2022.",1
AMTI,Ulcerative colitis,Phase 2,2022-12-23 00:00:00,"Phase 2 data at week 12 resulted in lower clinical remission (CR) rate in patients treated was 17.1% (12/70 patients) compared to a CR rate of 20.0% (7/35 patients) with placebo, noted December 23, 2022.",1
UNCY,Hyperphosphatemia,Phase 1,2022-12-28 00:00:00,"Trial met primary endpoint, noted December 28, 2022",0
ACST,Ataxia-Telangiectasia (A-T),Phase 3,2022-12-28 00:00:00,"Phase 3 pharmacokinetic(PK) study met all outcome measures, noted December 28, 2022.",0
GKOS,Dry Eye Disease (DED),Phase 2a,2023-01-10 00:00:00,"Phase 2a outcomes for GLK-301 demonstrated improvement in the quality of tear film, noted January 10, 2023.",1
BGNE,First-line chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),Approved,2023-01-19 00:00:00,"Approved January 19, 2023.",1
CMPX,Biliary Tract Cancer (cholangiocarcinoma),Phase 2,2023-01-19 00:00:00,"Phase 2 data presented at ASCO GI reported a 37.5% overall response rate (ORR) in 24 patients, and an ORR of 63.6% in a sub-group analysis, noted January 19, 2023.",1
LLY,Relapsed/refractory chronic lymphocytic leukemia,Approved,2023-01-27 00:00:00,"FDA Approved on January 27, 2023.",1
EOLS,Aesthetics,Phase 2,2023-01-28 00:00:00,"Phase 2 interim data presented at the 2023 IMCAS World Congress on indicated that the ""extra-strength"" formulation at 40U (units) achieved a duration profile of 6 months or 26 weeks, noted January 28, 2023.",1
CVAC,"Covid-19 vaccine, omicron variant",Phase 1,2023-01-30 00:00:00,"Phase 1 immunogenicity data reported that on day 29 at the 12µg dose level, CV0501 generated a ratio of post-boost to pre-boost serum neutralizing titers against BA.1 of 13.3, noted January 30, 2023.",0
IMVIQ,Diffuse Large B Cell Lymphoma (DLBCL),Phase 2,2023-02-13 00:00:00,"Phase 2b initial response data showed that from 6/8 patients evaluable for efficacy; 3 patients showed confirmed complete responses, 1 patient was assessed with stable disease as best response and 2 patients were assessed with progressive disease as best response; and 2 patients with poor level of baseline functionality (ECOG ≥ 2) failed to stay on study through to the first scan and therefore could not be evaluated, noted February 13, 2023.",1
TVTX,IgA nephropathy,Approved,2023-02-17 00:00:00,"FDA accelerated approval on February 17, 2023.",1
IONS,Hereditary Angioedema (HAE),Phase 2,2023-02-21 00:00:00,"Phase 2 open-label study data reinforce the treatment's potential to be a best-in-class prophylactic treatment for patients living with hereditary angioedema, noted February 21, 2023.",1
SNY,Hemophilia A,Approved,2023-02-23 00:00:00,"Approved February 23, 2023.",1
AMGN,Heart failure with reduced ejection fraction (HFrEF),CRL,2023-02-28 00:00:00,"CRL issued February 28, 2023.",0
EXEL,Renal Cell Carcinoma,Phase 3,2023-03-03 00:00:00,"Phase 3 trial did not meet its primary endpoint, noted March 3, 2023.",1
AMTI,Pouchitis,Phase 2,2023-03-03 00:00:00,"Additional Phase 3 data demonstrated oral's gut-restricted profile with tissue-level pharmacodynamics (PD) effects and no systemic exposure by design. Translational analysis reveals IL-10 biological responses in 3mg and 10mg dose arms, noted March 3, 2023.",1
CHRS,Pegfilgrastim biosimilar,Approved,2023-03-06 00:00:00,"Autoinjector approved March 6, 2023.",1
AMPH,Opioid overdose,Approved,2023-03-07 00:00:00,"Approved March 8, 2023.",1
NVIV,Complete Thoracic AIS A Spinal Cord Injury,Phase 3,2023-03-09 00:00:00,"Pivotal trial did not meet the primary endpoint, noted March 9, 2023.",1
ACAD,Rett Syndrome,Approved,2023-03-10 00:00:00,"Approved March 10, 2023.",1
ZVRA,induced Vasomotor Symptoms (iVMS) associated with menopause,Phase 1,2023-03-17 00:00:00,"Phase 2a PoC did not meet its primary endpoint of ability to decrease the frequency or severity of hot flashes in postmenopausal women. As a result, the company is pausing the program until a full dataset review, noted March 17, 2023",1
CNTB,Atopic dermatitis (AD),Phase 2b,2023-03-18 00:00:00,"Phase 2b data reported that baseline median Eczema Area and Severity Index (EASI) was 26.9. 54.5% of patients were considered severe, with a baseline Investigators Global Assessment (IGA) score of 4, noted March 18, 2023.",0
EDSA,Allergic contact dermatitis (ACD),Phase 2b,2023-03-18 00:00:00,"Phase 2b data presented at AAD reported a 60% average improvement in symptoms from baseline on the CDSI versus 39% for the vehicle treated patients, noted March 18, 2023.",1
RHHBY,Spinal Muscular Atrophy (SMA) type 2 and 3,Phase 2/3,2023-03-20 00:00:00,"Phase 2/3 data reported increases in motor function observed during the first year were maintained through the fourth year, while the overall rate of adverse events continued to decrease, noted March 20, 2023.",1
KRTX,Schizophrenia,Phase 3,2023-03-20 00:00:00,"Phase 3 trial met primary endpoint, noted March 20, 2023.",0
SELB,Chronic Refractory Gout,Phase 3,2023-03-21 00:00:00,"Phase 3 top-line data reported that both trials met their primary endpoints, noted March 21, 2023.",0
PHIO,Melanoma,Phase 1b,2023-03-22 00:00:00,"Phase 1b safety data reported no dose-limiting toxicity, and no drug-related severe adverse events or serious adverse events, noted March 22, 2023.",0
REGN,Homozygous familial hypercholesterolemia (HoFH) in children,Approved,2023-03-22 00:00:00,"Approved March 22, 2023.",1
INCY,Merkel cell carcinoma (MCC),Approved,2023-03-22 00:00:00,"FDA Approved on March 22, 2023.",1
IVVD,COVID-19 (prevention),Phase 2/3,2023-03-23 00:00:00,"Phase 2/3 study suggests clinically meaningful protection can be achieved at low neutralizing antibody titers, noted March 23, 2023.",1
PHAR,Activated phosphoinositide 3-kinase delta syndrome (APDS),Approved,2023-03-24 00:00:00,"Approved March 24, 2023.",1
NLSP,Narcolepsy,Phase 3,2023-03-27 00:00:00,"OLE trial data reported that the mean ESS score for these patients declined by approximately 10.2 (SD=5.83) points from their DB study baseline to month 6 in the OLE, noted March 27, 2023.",0
IONS,ATTR Amyloidosis,Phase 3,2023-03-27 00:00:00,"Phase 3 66-week data reported that trial met all three primary endpoints, noted March 27, 2023.",0
TAK,Pouchitis,Phase 3,2023-03-30 00:00:00,"Phase 4 met primary endpoint, noted March 30, 2023.",0
IMUX,Ulcerative colitis,Phase 2,2023-04-05 00:00:00,"Additional Phase 2 data reported a dose-linear increase in clinical remission as compared to placebo at week 50 with an exploratory statistical analysis confirming that the 30 mg dose of vidofludimus calcium was statistically superior in achieving clinical remission, with a 33.7% absolute improvement over placebo, noted April 5, 2023.",1
AGLE,Classical Homocystinuria,Phase 1/2,2023-04-12 00:00:00,"Phase 1/2 data reported that treatment with pegtarviliase lowered total homocysteine levels in participants when compared to baseline values, and in the third cohort (1.35 mg/kg) did not show a consistent reduction in total homocysteine levels compared to baseline, noted April 12, 2023.",1
HRMY,22q11.2 Deletion Syndrome,Phase 2,2023-04-13 00:00:00,"Additional Phase 2 data reported a statistically significant improvements in PARS-R, total score and all 5 subscales of ADAMS and all 5 subscales of ABC-C, noted April 13, 2023.",1
HGEN,Chronic myelomonocytic leukemia (CMML),Phase 2,2023-04-14 00:00:00,"Phase 2 preliminary study results reported that 6 subjects demonstrated clinical benefit, with ten grade 3/4 Serious Adverse Events, noted April 14, 2023.",1
VACC,Human papillomavirus (HPV),Phase 1/2,2023-04-17 00:00:00,"Additional Phase 1/2a data reported that treatment was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events and no product-related SAEs, noted April 17, 2023.",1
ZYME,Solid Tumors,Phase 1,2023-04-18 00:00:00,"Additional data reported that anti-tumor activity was observed in breast cancer and gastric cancer PDXs representing a range of HER2 expression, noted April 18, 2023.",1
IMRX,Solid tumors,Phase 1,2023-04-18 00:00:00,"Phase 1 data presented at AARC showed that dosing was well tolerated with no dose limiting toxicities (DLTs) or serious adverse events (SAEs) observed, noted April 18, 2023.",1
SONN,Solid tumors,Phase 1,2023-04-18 00:00:00,"Phase 1 data presented at AACR reported no dose limiting toxicities, and 5 of the first 14 patients (36%) have evidence of clinical benefit, noted April 18, 2023.",1
RHHBY,Diffuse Large B-Cell Lymphoma,Approved,2023-04-19 00:00:00,"FDA Approved on April 19, 2023.",1
AVIR,COVID-19,Phase 2,2023-04-25 00:00:00,"Fast Track Designation granted on April 25, 2023.",0
IONS,Amyotrophic lateral sclerosis (SOD1-ALS),Approved,2023-04-25 00:00:00,"FDA granted accelerated approval on April 25, 2023.",1
CLNN,Multiple Sclerosis,Phase 2,2023-04-25 00:00:00,"Phase 2 topline data presentated at AAN reported that the primary BC-LCLA outcome LS-mean difference was 3.13 and 2 of 3 key secondary outcomes were significant, noted April 25, 2023.",1
INBX,Chondrosarcoma and mesothelioma,Phase 1,2023-04-26 00:00:00,"Clinical hold lifted, noted April 26, 2023. Phase 1 combination cohorts are expected to begin reading out by year end 2023 and data from the registration-enabling trial in unresectable or metastatic conventional chondrosarcoma is expected during the 2H 2024.",0
LLY,Systemic lupus erythematosus (SLE),Phase 2,2023-04-27 00:00:00,"Phase 2 to be moved to from Lupus to Atopic dermatitis after disappointing results, noted April 27, 2023.",0
KPRX,Retinitis Pigmentosa (RP),Phase 1,2023-05-01 00:00:00,"Phase 1 abstract presented at ASNR23 on May 1, 2023",1
AGEN,RSV vaccine,Approved,2023-05-03 00:00:00,"FDA Approved on May 3, 2023.",1
SABS,Type A and Type B influenza,Phase 2a,2023-05-04 00:00:00,"Phase 2a first fully-human multi-epitope binding broadly neutralizing immunoglobulin antibody therapeutic being developed for treatment of high-risk patients demonstrates safety and efficacy in Phase 1 and 2a trials, noted May 4, 2023",1
PCSA,Gastroparesis,Phase 2a,2023-05-06 00:00:00,"Phase 2a data reported at DDW noted that treatment improved both gastroparesis symptom scores and gastric emptying rate, noted May 6, 2023.",1
IDYA,Non-metastatic uveal melanoma (UM),Phase 1/2,2023-05-09 00:00:00,"Phase 2 data reported that treatment showed evidence of anti-tumor activity, noted May 9, 2023.",1
PLX,Fabry disease,Approved,2023-05-10 00:00:00,"Approved May 10, 2023.",1
CELC,ER+/HER2- Breast Cancer,Phase 1b,2023-05-12 00:00:00,"Phase 1b data shared at ESMO Breast Cancer reported that for treatment-naïve patients median PFS was 45.8 months and 48.6 months in the expansion arm, noted May 12, 2023.",1
ABBV,Botox in the cheeks,Approved,2023-05-15 00:00:00,"FDA Approved on May 15, 2023.",1
ANIP,Osteoporosis,Approved,2023-05-15 00:00:00,"ANDA approved May 15, 2023.",1
LGND,Non-alcoholic steatohepatitis (NASH) and fibrosis,Phase 2b,2023-05-16 00:00:00,"Phase 2b data reported that trial met primary endpoint, noted May 16, 2023.",0
CLLS,Acute myeloid leukemia (AML),Phase 1,2023-05-17 00:00:00,"Phase 1 preliminary data presented at ASGCT showed that adding alemtuzumab to the FC LD regimen was associated with sustained lymphodepletion and significantly higher UCART123 cell expansion, which correlated with improved anti-tumor activity, noted on May 17, 2023.",1
AVRO,Cystinosis,Phase 1/2,2023-05-18 00:00:00,"Phase 1/2 data presented at ASGCT reported sustained engraftment and durable reduction in leukocyte cystine levels across all patients, noted May 18, 2023.",1
CADL,Glioma,Phase 1,2023-05-19 00:00:00,"Additional Phase 1 data presented at ASGCT reported a median overall survival rate at 11.8 months after a single injection, noted May 19, 2023.",1
HEPA,Non-alcoholic steatohepatitis (NASH),Phase 2,2023-05-22 00:00:00,"Phase 2 topline data met primary and secondary endpoints, including improvement in liver function and multiple NASH biomarkers, noted May 22, 2023.",1
ICVX,RSV/human Metapneumovirus (hMPV),Phase 1,2023-05-23 00:00:00,"Phase 1 data reported that the proportion of subjects experiencing any systemic AE within seven days was 25-41%, and similar to 35% for placebo, with induced geometric mean titers (GMTs) in RSV-A neutralizing antibody titers (nAbs) of up to approximately 16,100 IU/mL compared to approximately 2,600 IU/mL for placebo at Day 28, noted May 23, 2023.",0
PLRX,Idiopathic Pulmonary Fibrosis (IPF),Phase 2a,2023-05-24 00:00:00,"Phase 2a additional f\data presented at ATS 2023 showed that bexotegrast was well tolerated across all four dose groups with bexotegrast-treated participants experiencing a reduction in forced vital capacity (FVC) decline over 12 weeks versus placebo, on and off background therapy., noted May 24, 2023.",1
ZLAB,Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter),Approved,2023-05-24 00:00:00,"Approved May 24, 2023.",1
XLO,Solid Tumors,Phase 1,2023-05-25 00:00:00,"Phase 1 preliminary anti-tumor activity observed in a patient with PD-L1 negative advanced non-small cell lung cancer, favorable preliminary safety profile for XTX101 observed at the recommended Phase 2 dose of 150 mg once every six weeks, noted May 25, 2023.",1
VNDA,Motion sickness,Phase 3,2023-05-25 00:00:00,"Phase 3 data reported that the 170 mg and 85 mg tradipitant doses were shown to be superior to placebo in preventing vomiting with only 18.3% and 19.5% of participants experiencing vomiting on tradipitant 170 mg and 85 mg respectively, as compared to 44.3% of participants on placebo, noted May 25, 2023.",1
REGN,Melanoma,Phase 1,2023-05-25 00:00:00,"Additional Phase 1 data from ASCO reported an ORR of 63% (25 of 40 patients), including 6 complete responses (CR) and 19 partial responses (PR) in the initial cohort, with a ORR of 63% in the confirmatory cohort, and 56% in the Prior neo/adjuvant systemic therapy cohort, noted May 25, 2023.",0
LXRX,Heart failure,Approved,2023-05-26 00:00:00,"Approved May 26, 2023.",1
ABBV,Systemic Lupus Erythematosus (SLE),Phase 2,2023-05-31 00:00:00,"Phase 2 data reported that trial met primary endpoint, noted May 31, 2023.",0
TVTX,Classical homocystinuria (HCU),Phase 1/2,2023-05-31 00:00:00,"Additional Phase 2 data reported that treatment was well tolerated, with dose-dependent reductions in tHcy as previously observed in the highest BIW dosed cohorts, noted July 6, 2023.",1
CNTB,Ulcerative Colitis (UC),Phase 2b,2023-06-01 00:00:00,"Phase 2b maintenance data reported that 57% (12/21) of patients with clinical response at the end of the induction period achieved clinical remission at the end of the maintenance period, noted June 1, 2023.",1
DCPH,Gastrointestinal Stromal Tumors (GIST) - second-line,Phase 3,2023-06-01 00:00:00,"Phase 3 data reported that the mPFS (90% CI) by IRR was 6.44 (2.89, 8.31) months and ORR was 21.1%, noted June 1, 2023.",0
ZLAB,Gastrointestinal Stromal Tumors (GIST) - second-line,Phase 3,2023-06-01 00:00:00,"Phase 3 data reported that the mPFS (90% CI) by IRR was 6.44 (2.89, 8.31) months and ORR was 21.1%, noted June 1, 2023.",0
ZLAB,Ovarian cancer,Phase 3,2023-06-01 00:00:00,"Phase 3 data reported a complete and partial responses, both confirmed, were observed in 12 (25.5%) and 15 (31.9%) niraparib-treated patients and 3 (11.5%) and 5 (19.2%) placebo-treated patients, respectively, leading to a confirmed ORR of 57.4% with niraparib and 30.8% with placebo, noted June 1, 2023.Phase 3 data reported a complete and partial responses, both confirmed, were observed in 12 (25.5%) and 15 (31.9%) niraparib-treated patients and 3 (11.5%) and 5 (19.2%) placebo-treated patients, respectively, leading to a confirmed ORR of 57.4% with niraparib and 30.8% with placebo, noted June 1, 2023.",1
PFE,Serious Bacterial Infection,Phase 3,2023-06-01 00:00:00,"Phase 3 data reported that 5/12 (41.7%) of the ATM-AVI ± MTZ patients with infections due to confirmed MBL-producing Gram-negative bacteria were cured at TOC versus 0/3 (0%) of those on best available therapy (BAT), noted June 1, 2023.",0
AUTL,B-Cell Acute Lymphoblastic Leukemia,Phase 2,2023-06-02 00:00:00,"Phase 2 safety and efficacy data presented at ASCO showed that 76% of patients treated achieved a response (CR/CRi), primary endpoint has been met based on previously communicated interim analysis, noted June 2, 2023",1
BNTX,"Cancer, PD-(L)1-resistant non-small cell lung cancer",Phase 1/2,2023-06-02 00:00:00,"Phase 1/2 data reported that the ORR was 29.6% and DCR was 70.4%, including one complete response, 7 partial responses and 11 patients with stable disease, noted June 2, 2023.",0
AFMD,EGFR-expressing solid tumors,Phase 1/2,2023-06-03 00:00:00,"Phase 1/2 interim data presented at ASCO reported that 7 out of 15 heavily pre-treated patients with tumor reductions, including 2 confirmed partial responses and 5 patients exhibiting stable disease, noted June 3, 2023.",1
SGEN,Solid Tumors,Phase 1,2023-06-03 00:00:00,"Phase 1 data at ASCO reported that treatment-emergent adverse events (TEAEs) were observed in 88.5% of pts: 50.7% were Grade ≥ 3 (21.6% related), and 37.2% were serious (8.1% related); 6.1% of pts discontinued treatment due to TEAEs, noted June 3, 2023.",1
GNPX,Non-small cell lung cancer (NSCLC),Phase 1,2023-06-03 00:00:00,"Phase 1 data shared at ASCO reported that treatment was well tolerated, and there were no dose limiting toxicities, noted June 3, 2023.",1
CHRS,Metastatic or recurrent triple-negative breast cancer (TNBC),Phase 3,2023-06-03 00:00:00,"Phase 3 data presented at ASCO reported a statistically significant improvement in PFS by BICR was demonstrated for the toripalimab arm in the PD-L1 positive subgroup, noted June 3, 2023.",1
STTK,Ovarian Cancer,Phase 1a,2023-06-05 00:00:00,"Phase 1a monotherapy data shared at ASCO reported that the best response was stable disease in 6/27 response evaluable (22%) pts, noted June 5, 2023.",1
MRK,Prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (D+/R-),Approved,2023-06-05 00:00:00,"Approved on June 5, 2023.",1
LEGN,Multiple Myeloma,Phase 3,2023-06-05 00:00:00,"Phase 3 results shared at ASCO demonstrated a statistically significant improvement in progression-free survival, with a hazard ratio of 0.26, noted June 5, 2023",1
PGEN,Ovarian cancer,Phase 1,2023-06-05 00:00:00,"Phase 1 data presented at ASCO demonstrated expansion and persistence when delivered via either intraperitoneal or intravenous infusion without lymphodepletion or via intravenous infusion after lymphodepletion demonstrating the effectiveness of mbIL15, noted June 5, 2023.",1
GILD,Refractory Large B-cell Lymphoma,Phase 1,2023-06-05 00:00:00,"Phase 1 data presented at ASCO showed that Yescarta is the first treatment in nearly 30 years to demonstrate a significant improvement in survival in this patient population. The treatment resulted in a 27.4% Reduction in Risk of Death, Corresponding to a 38% Relative Improvement in OS, Despite 57% of Patients Subsequently Receiving Cell Therapy Off Protocol, noted June 5, 2023",1
ERAS,Solid Tumors,Phase 1b,2023-06-05 00:00:00,"Deprioritized as dose escalation safety data do not support continued evaluation of regimen tested, noted June 5, 2023.",1
YMAB,High-risk neuroblastoma (HR-NB) commonly,Phase 2,2023-06-06 00:00:00,"Phase 2 interim data presented at ASCO reported that the ORR was 58% in patients with refractory disease and 42% in patients with relapsed disease, noted June 6, 2023.",1
BXRX,Neuromuscular blockade (NMB) in patients undergoing elective surgery,Phase 2,2023-06-07 00:00:00,"hase 2 primary efficacy endpoint was the proportion of patients that met criteria for Good or Excellent intubating conditions using a standardized scale. All patients, across regimens, met the primary efficacy criteria, noted June 7, 2023.",0
ADCT,Diffuse Large B-Cell Lymphoma,Phase 2,2023-06-09 00:00:00,"Phase 2 data presented at EHA showed that 31% of patients who achieved a complete response remained event-free for two or more years and did not need new anticancer therapy, noted June 9, 2023.",1
BGNE,Follicular Non-Hodgkin Lymphoma,Phase 2,2023-06-09 00:00:00,"Phase 2 data presented at EHA reported that the OS rate at 24 months was 77.3%(zanubrutinib plus obinutuzumab) and 71.4% (obinutuzumab), with median OS not reached (zanubrutinib plusobinutuzumab) and 34.6 months, noted June 9, 2023.",1
VOR,Acute myeloid leukemia (AML),Phase 1/2,2023-06-09 00:00:00,"Phase 1/2a additional data presented at EHA showed that patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism, noted June 9, 2023.",1
EDIT,Sickle Cell Disease,Phase 1/2,2023-06-09 00:00:00,"Phase 1/2 data presented at EHA reported that all five patients treated with EDIT-301 successfully engrafted and all four RUBY patients treated are free of vaso-occlusive events since infusion, noted June 9, 2023.",1
IMGN,"Relapse/Refractory AML, ALL, BPDCN",Phase 2,2023-06-09 00:00:00,"Phase 2 interim data reported that the objective response rate was 73% (22/30 patients), and an additional patient achieved a CR post-transplant, noted June 9, 2023.",1
NVS,Paroxysmal nocturnal hemoglobinuria (PNH),Phase 3,2023-06-09 00:00:00,"Phase 3 data presented at EHA showed that monotherapy significantly improved Hb levels vs. SoC without the need for RBCTs. By maintaining intravascular hemolysis control and reducing C3 deposition leading to EVH, IPTA monotherapy led to an expected increase in PNH RBC survival to the extent that they formed >90% of the total RBC population, noted June 9, 2023",1
EDIT,Transfusion-Dependent Beta Thalassemia (TDT),Phase 1/2,2023-06-09 00:00:00,"Phase 1/2 first patient demonstrated successful neutrophil and platelet engraftment, and, at one and a half months post-infusion, the patient's response resembles that of the first four RUBY patients, noted June 9, 2023.",1
AZN,Metastatic breast cancer,Phase 3,2023-06-12 00:00:00,"Phase 3 trial results showed the combination reduced the risk of disease progression or death by 40% vs. Faslodex alone, noted June 12, 2023",1
CANF,Pancreatic Cancer,Phase 1a,2023-06-13 00:00:00,"Preclinical studies demonstrated robust effect reached 90% inhibition of pancreatic cancer growth, IND underway, noted June 13, 2023.",1
ELOX,Cystic fibrosis,Phase 2,2023-06-14 00:00:00,"Phase 2 data demonstrated clinically relevant improvement in percent predicted forced expiratory volume (ppFEV1) based on final data assessment, noted June 14, 2023.",1
BGNE,Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL),Phase 2,2023-06-15 00:00:00,"Phase 2 long-term follow-up demonstrated high rates of durable undetectable minimal residual disease (MRD) in CLL/SLL patients administered BOVen. Of the 46 patients meeting MRD criteria to cease treatment, median time from end of treatment to MRD conversion was 29.8 months, noted June 15, 2023.",1
TNXP,Fibromyalgia,Phase 3,2023-06-15 00:00:00,"Phase 3 met the primary endpoint on its RELIEF trial, noted June 15, 2023",0
ALDX,Allergic conjunctivitis,Phase 3,2023-06-15 00:00:00,"Phase 3 top-line data met primary and all secondary endpoints, noted on June 15, 2023.",0
BMY,Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM),Approved,2023-06-16 00:00:00,"FDA Approval on June 16, 2023",1
GILD,Multiple Myeloma,Phase 2,2023-06-19 00:00:00,"Phase 2 clinical hold received by the FDA after a recent patient death, noted June 19, 2023.",0
ARDS,Ventilator associated pneumonia (VAP) / Staphylococcus aureus,Phase 3,2023-06-20 00:00:00,"FDA granted Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), noted June 20, 2023. The official determination regarding using the LPAD pathway will be made after the Company's request following the filing of the biologics license application (BLA).",-1
HALO,Generalized Myasthenia Gravis (gMG),Approved,2023-06-20 00:00:00,"FDA Approved on June 20, 2023.",1
CTXR,Hemorrhoids,Phase 2b,2023-06-20 00:00:00,"Phase 2b enrollment completed, noted April 3, 2023. Phase 2b data provided meaningful reduction in symptom severity when compared to individual components alone, noted June 20, 2023.",1
PIRS,Asthma,Phase 2a,2023-06-21 00:00:00,"Phase 2a AstraZeneca communicated to Pieris its decision to discontinue and cease dosing in the ongoing clinical studies, the decision was based on lung findings from a non-clinical 13-week GLP toxicology study, which are not a concern for the active clinical studies but do not support long-term use and progression to later-stage development, noted June 21, 2023.",-1
VTGN,Major depressive disorder (MDD),Phase 1,2023-06-21 00:00:00,"Phase 1 study results showed that dosing was well-tolerated and demonstrated a favorable safety and tolerability profile across single and multiple dose intranasal administrations, noted June 21, 2023.",1
VACC,Hepatitis B (HBV),Phase 1/2,2023-06-21 00:00:00,"Phase 1b/2a data at EASL showed that all participants who received and experienced a >0.5 log10 reduction in HBsAg had durable responses with reductions in HBsAg persisting through to the last measurement eight months post-final dose, noted June 21, 2023.",1
SPRC,Tourette Syndrome,Phase 2b,2023-06-21 00:00:00,"Phase 2b IRB approval to initiate study, noted June 21, 2023.",1
JNJ,Influenza,Phase 2a,2023-06-22 00:00:00,"FDA has granted Fast Track designation (FTD), noted June 22, 2023.",0
RHHBY,Duchenne Muscular Dystrophy,Approved,2023-06-22 00:00:00,"FDA acelerated Approval on June 22, 2023.",1
ERAS,Glioblastoma Multiforme,Phase 1,2023-06-22 00:00:00,"DA granted orphan drug designation (ODD), noted June 22, 2023.",0
ALZN,Dementia related to Alzheimer's,Phase 2a,2023-06-22 00:00:00,"Phase 2a topline results identified a safe & appropriate dose to explore the potential to distribute more lithium to the brain but at lower systemic exposure, resulting in an improved safety profile compared to currently marketed lithium, noted June 22, 2023",1
ICPT,Primary Biliary Cholangitis (PBC),Phase 2a,2023-06-23 00:00:00,"Phase 2a data presented at EASL showed that the Combination was well-tolerated with lowest rates of pruritus observed in OCA 5-10 mg + bezafibrate 400 mg treatment arm, noted June 23, 2023.",1
LLY,Type 2 diabetes,Phase 2,2023-06-24 00:00:00,"Phase 2 additional data achieved a mean reduction in A1C up to 2.1% at 26 weeks, noted June 24, 2023.",1
LLY,Obesity,Phase 2,2023-06-24 00:00:00,"Phase 2 met primary and secondary endpoints, noted June 24, 2023.",0
IVA,Non-alcoholic steatohepatitis (NASH),Phase 2b,2023-06-24 00:00:00,"Phase 2b additional data presented on EASL showed that lanifibranor significantly increases the levels of adiponectin and that this increase is correlated with the improvements of cardiometabolic markers, including insulin resistance, glycemic control, lipid metabolism, and systemic inflammation, noted June 24, 2023.",1
LLY,Obesity,Phase 3,2023-06-24 00:00:00,"Phase 3 efficacy and safety data shared at ADA met both co-primary endpoints and all key secondary endpoints compared to placebo for both estimands, with those taking tirzepatide achieving a mean weight reduction of 13.4% on 10 mg and 15.7% on 15 mg compared to 3.3% on placebo for the efficacy estimand, noted June 24, 2023.",1
ALNY,Hepatitis B (HBV),Phase 2,2023-06-24 00:00:00,"Phase 2 24 or 48 weeks plus up to 48 weeks of PEG-IFN-⍺ (cohorts 4 and 5 combined), 26% (8/31) achieved HBsAg loss at the end of treatment and 16% (5/31) sustained HBsAg loss 24 weeks after the end of treatment, noted June 24, 2023.",1
VIR,Hepatitis B,Phase 1,2023-06-24 00:00:00,"Phase 1 data showed that treatment has a shorter terminal half-life and was cleared faster in participants with higher baseline HBsAg, noted June 24, 2023.",1
TAK,Alpha-1 Liver Disease,Phase 2,2023-06-24 00:00:00,"Phase 2 data presented at EASL showed that at week 48, patients receiving 25, 100, or 200 mg fazirsiran achieved serum Z-AAT reductions of 74%, 89%, and 94%, respectively, versus an increase of 9% observed in patients receiving placebo, noted June 24, 2023.",1
BNTC,Oculopharyngeal muscular dystrophy (OPMD),Phase 1/2,2023-06-26 00:00:00,"Phase 1b/2a IND clearance on June 26, 2023.",0
ACET,Non-Hodgkin’s lymphoma,Phase 1,2023-06-26 00:00:00,"Phase 1 safety and efficacy data demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels in patients with median 4 prior lines of therapy, a Six-month CR rate consistent with autologous CAR T cell therapy, noted June 26, 2023.",1
CGTX,Mild-to-Moderate Alzheimer's Disease,Phase 2,2023-06-28 00:00:00,"Phase 2 study met its primary endpoints for safety and tolerability and showed positive effects for CT1812-treated participants as measured via quantitative electroencephalogram (qEEG), noted June 28, 2023.",1
TEVA,Inflammatory diseases,CRL,2023-06-28 00:00:00,"Third CRL issued June 28, 2023. Resubmission planned.",0
SLS,Malignant pleural mesothelioma (MPM),Phase 1,2023-06-28 00:00:00,"Phase 1 topline data reported that the median overall survival for patients who entered the study as Stage IV patients was 62.3 weeks, noted June 28, 2023.",0
SRRK,Spinal muscular atrophy (SMA),Phase 2,2023-06-30 00:00:00,"Phase 2 36-month extension data presented at the Cure SMA Conference showed that continued treatment with apitegromab over the extended treatment period was associated with substantial and sustained improvement in motor function, noted June 30, 2023.",1
KZIA,Brain Metastases,Phase 1,2023-07-06 00:00:00,"FDA awarded Fast Track Designation, noted July 6, 20223.",0
TNGX,Solid Tumors,Phase 1/2,2023-07-10 00:00:00,"Phase 1/2 dosing initiated, noted July 10, 2023.",0
CGTX,Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (AMD),Phase 1,2023-07-11 00:00:00,"Phase 2 trial dosing initiated, noted July 11, 2023.",0
CRBU,B-Cell Non-Hodgkin Lymphoma,Phase 1,2023-07-13 00:00:00,"Phase 1 update reported a 94% overall response rate (ORR), 69% complete response (CR) rate, and 44% CR rate at ≥6 months following a single dose of CB-010, with 24 months as the longer CR maintained to date, noted July 13, 2023.",0
FWBI,Exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP),Phase 2,2023-07-13 00:00:00,"Phase 2 topline Initial data from the study indicated the enhanced adrulipase formulation was safe and well tolerated and demonstrated an improvement over prior formulations of adrulipase. However, the preliminary data also indicate that it is likely the primary efficacy endpoint was not achieved, noted July13,. 2023.",1
IMMX,Solid tumors,Phase 1/2,2023-07-17 00:00:00,"Phase 1b/2a additional data noted that tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory metastatic colorectal cancer and received 8 median lines of therapy prior to IMX-110 + tislelizumab, noted July 17, 2023.",1
ACIU,Neurodegenerative diseases (NDD),Phase 1,2023-07-18 00:00:00,"Updated biomarker data reported that ACI-15916shows significantly improved specific binding to pathological a-syn aggregates in brain sections from different a-synucleinopathy cases, noted July 18, 2023.",1
PFE,Streptococcus Vaccine,Phase 2,2023-07-19 00:00:00,"Phase 2 results showed that the investigational vaccine, GBS6, was generally well-tolerated and generated robust maternal antibody responses that were efficiently transferred to infants, noted July 19, 2023.",1
INCY,Chronic Graft versus host disease (cGvHD),Phase 2,2023-07-24 00:00:00,"Phase 2 trial results met its primary endpoint across all cohorts with an overall response rate (ORR) of 74% at a dose of 0.3 mg/kg administered every two weeks, noted July 24, 2023.",0
KOD,Diabetic macular edema (DME),Phase 3,2023-07-24 00:00:00,"Phase 3 trial did not meet the primary endpoint, noted July 24, 2023.",1
DYAI,COVID-19 booster vaccine,Phase 1,2023-07-24 00:00:00,"Phase 1 safety data reporter no Serious Adverse Events or Adverse Events of Special Interest have been reported to date, noted July 24, 2023",0
TARS,Demodex Blepharitis,Approved,2023-07-25 00:00:00,"FDA approved on July 25, 2023.",1
STOK,Dravet Syndrome,Phase 1/2,2023-07-25 00:00:00,"Phase 1/2 data presented showed that patients treated with 2 or 3 initial doses experienced substantial and sustained reductions in convulsive seizure frequency; Median reductions at 3 months after last dose of 80% and 89% at 6 months after last dose, compared to baseline, noted July 25, 2023.",1
STOK,Dravet Syndrome,Phase 1/2,2023-07-25 00:00:00,"Phase 1/2a new data suggest clinical benefit for patients 2 to 18 years of age treated with multiple doses of STK-001. The observed reductions in convulsive seizure frequency as well as substantial improvements in cognition and behavior support the potential for disease modification in a highly refractory patient population, noted July 25, 2024",1
STOK,Dravet syndrome,Phase 1/2,2023-07-25 00:00:00,"Phase 1/2a OLE OLE data of STK-001 (30mg, 45mg) showed a Sustained reductions in convulsive seizure frequency and improvements in cognition and behavior, noted July 25, 2023.",1
MRK,Pneumococcal Conjugate Vaccine,Phase 3,2023-07-27 00:00:00,"Phase 3 trial met primary endpoints, noted July 27, 2023.",0
URGN,Low grade non-muscle invasive bladder cancer (LG-NMIBC),Phase 3,2023-07-27 00:00:00,"Phase 3 trial met primary endpoint with 79.2% rate of complete response at 3-months following the initial treatment, noted July 27, 2023.",1
QLGN,"Pancreatic cancer, Prostate cancer and other solid tumors",Phase 1a,2023-08-01 00:00:00,"IND cleared by FDA, noted August 1, 2023",0
ALT,Non-alcoholic fatty liver disease (NAFLD),Phase 2b,2023-08-01 00:00:00,"Phase 2b IMPACT trial enrollment initiated, noted August 1, 2023.",0
BIIB,Postpartum Depression,Approved,2023-08-04 00:00:00,"Approved August 4, 2023.",1
SAGE,Postpartum Depression,Approved,2023-08-04 00:00:00,"Approved August 4, 2023.",1
VTGN,Social Anxiety Disorder (SAD),Phase 3,2023-08-07 00:00:00,"Phase 3 topline data met its primary endpoint, noted August 7, 2023.",0
PASG,GM1 gangliosidosis (GM1),Phase 1/2,2023-08-07 00:00:00,"Phase 1/2 initial safety data from cohorts 1-4 up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profile, noted August 7, 2023.",1
CNSP,Glioblastoma (GBM) (adult),Phase 2,2023-08-14 00:00:00,"Phase 2 interim update demonstrated its capability to be an innovative treatment in GBM that is safe and well tolerated, which has the potential to be a novel and effective therapy for this disease, noted August 14, 2023.",1
NVS,Wet macular degeneration,Phase 3,2023-08-15 00:00:00,"Phase 3 trial met its primary endpoint, noted August 15, 2023.",0
REGN,"Wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR)",Approved,2023-08-18 00:00:00,"Approved August 18, 2023.",1
PFE,Respiratory Syncytial Virus (RSV) in infants,Approved,2023-08-21 00:00:00,"FDA approval on August 21, 2023.",1
RHHBY,1L Non-Small Cell Lung Cancer (NSCLC) PD-L1 high,Phase 3,2023-08-23 00:00:00,"Phase 3 data reported that median overall survival estimates of 22.9 months in the tiragolumab plus Tecentriq arm, and 16.7 months in the Tecentriq monotherapy arm, noted August 23, 2023.",0
GILD,"COVID-19 in people with mild, moderate and severe hepatic impairment",Approved,2023-08-24 00:00:00,"Approved August 24, 2023.",1
ESPR,Cardiovascular Diseases,Phase 3,2023-08-26 00:00:00,"Phase 3 total event data presented at ESC reported that bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3, noted August 26, 2023.",1
BBIO,Amyloid cardiomyopathy (ATTR-CM),Phase 3,2023-08-27 00:00:00,"Phase 3 data presented at ESC reported an 81% survival rate on acoramidis and over 30 months, patients survived more and were hospitalized less than has been seen in prior controlled studies, noted August 27, 2023.",1
VALN,Chikungunya Vaccine for adolecents,Phase 3,2023-08-28 00:00:00,"Phase 3 trial data reported that VLA1553 was generally safe and well tolerated in adolescents aged 12 to 17 years, regardless of previous CHIKV infection, noted August 28, 2023.",1
NVS,"Atherosclerotic cardiovascular disease (ASCVD), increased risk of ASCVD or heterozygous familial hypercholesterolemia (HeFH)",Phase 3,2023-08-28 00:00:00,"Phase 3 data reported that eight in ten patients achieved target LDL-C threshold, noted August 28, 2023.",1
OCUP,Diabetic Retinopathy (DR) / Macular Edema (DME),Phase 2,2023-08-28 00:00:00,"Phase 2 data reported that APX3330 achieved statistical significance in preventing clinically meaningful progression of diabetic retinopathy, noted August 28, 2023.",1
MRK,"First-line, lower-risk Myelodysplastic syndromes (MDS)",Approved,2023-08-28 00:00:00,"Approved August 28, 2023.",1
BFRI,Actinic Keratosis on face & scalp,Phase 1,2023-08-28 00:00:00,"Phase 1 data reported that treatment was generally well tolerated and all TEAEs were transient, noted August 28, 2023.",1
LIAN,Obstructive hypertrophic cardiomyopathy (oHCM),Phase 3,2023-08-28 00:00:00,"Phase 3 data presented at ESC reported that treatment demonstrated improvement in Valsalva LVOT peak gradient, LVOT obstruction, clinical symptoms, health status, cardiac biomarkers, and cardiac structure in Chinese oHCM patients, noted August 28, 2023.",1
TNXP,fibromyalgia-type Long COVID,Phase 2,2023-09-05 00:00:00,"Phase 2 topline data did not achieve the pre-specified primary endpoint of improving Long COVID pain intensity scores at Week 14, noted September 5, 2023.",1
AUTL,Pediatric Acute lymphoblastic leukemia (ALL),Phase 1,2023-09-05 00:00:00,"Phase 1 data presented at the Blood journal showed that of 10 responding patients, 5 had emergence of MRD (2) or frank relapse (3) with CD19 and CD22 expressing disease associated with loss of CAR T-cell persistence. Importantly, there were no cases of relapse due to antigen-negative escape, with a median follow-up of 8.7 months. Overall survival was 75% at 6 and 12 months. Six and 12-month event free survival (EFS) were 75% and 60% respectively, noted September 5, 2023.",1
VIR,Hepatitis B,Phase 2,2023-09-06 00:00:00,"Additional Phase 2 data significantly increased HBsAg seroconversion rate is strongly associated with BRII-179 treatment and correlates with the increased rate of HBsAg loss3, noted September 6, 2023.",1
TNGX,Solid Tumors,Phase 1a,2023-09-06 00:00:00,"IND cleared by FDA, noted September 6, 2023. Phase 1/2 clinical trial to commence 1H 2024.",0
TRVN,Diabetic neuropathic pain (DNP),Phase 1,2023-09-06 00:00:00,"Phase 1 data demonstrated a statistically significant analgesic effect in the capsaicin-induced model, noted on September 6, 2023.",1
PFE,Lyme disease,Phase 2,2023-09-07 00:00:00,"Phase 2 data showed that participants seroconverted after the booster dose, yielding seroconversion1 rates (SCRs) of 95.3% and 94.6% for all outer surface protein A (OspA) serotypes in all age groups, noted September 7, 2023.",1
RNA,Myotonic dystrophy type 1 (DM1),Phase 1/2,2023-09-09 00:00:00,"Phase 1/2 topline data analysis presented at the Myotonic Dystrophy Foundation Annual Conference reported directional improvements in myotonia (vHOT) as early as 6 weeks after dosing with a sustained effect at Month 6, noted September 9, 2023.",1
AZN,Non-small cell lung cancer (NSCLC),Phase 3,2023-09-09 00:00:00,"Phase 3 data presented at WCLC reported a reduced the risk of disease progression or death by 38% compared to TAGRISSO alone and a combination extended median PFS by 8.8 months, noted September 9, 2023.",1
CING,ADHD,Phase 3,2023-09-09 00:00:00,"Phase 3 trial full results reported improvements on the PERMP scores with a trend towards statistical significance for PERMP ratings over the 16-hour period, noted September 9, 2023.",1
MRKR,Lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment,Phase 1,2023-09-11 00:00:00,"Phase 1 clinical update showed that patients with Non-Hodgkin's Lymphoma who relapsed after anti-CD19 CAR T cell therapy tolerated initial dose level well and achieved complete response after MT-601 treatment, noted September 11, 2023.",1
EYPT,Non-proliferative diabetic retinopathy (NPDR),Phase 2,2023-09-11 00:00:00,"Phase 2 interim analysis of masked data showed that EYP-1901 is well tolerated with no reported drug-related ocular or systemic serious adverse events, noted September 11, 2023.",1
ARWR,Healthy volunteers and Asthma,Phase 1/2,2023-09-11 00:00:00,"Phase 1/2 preliminary clinical data achieved mean target gene knockdown of up to 90% with a maximum of 95% after a single inhaled administration, noted Septemeber 11, 2023.",1
NXTC,PD-1 axis inhibitor refractory non-small cell lung cancer (NSCLC),Phase 2,2023-09-12 00:00:00,"Phase 2 data reported that 28% of patients (5/18) had durable clinical benefit with three of these being confirmed responses, noted September 12, 2023.",0
SCLX,Acute lower back pain (LBP),Phase 2,2023-09-14 00:00:00,"Phase 2 data reported that none of the subjects in the active group and 3 (8.1%) subjects in placebo group had AEs of special interest, with a meaningful reduction of pain over the first week, noted September 14, 2023.",1
AVXL,Mild to moderate Alzheimer’s disease,Phase 2/3,2023-09-14 00:00:00,"Phase 2b/3 full data reported that the least-squares mean (LSM) change from baseline to 48 weeks between the blarcamesine and placebo groups were −1.783; for ADAS-Cog13, and −0.456 for CDR-SB in patients with early Alzheimer's disease, noted September 14, 2023.",0
GILD,Large B-cell lymphoma (LBCL) after one prior line of therapy who were deemed ineligible for high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT),Phase 2,2023-09-18 00:00:00,"Phase 2 trial met its primary endpoint, noted September 18, 2023.",0
KNTE,Solid Tumors,Phase 1,2023-09-18 00:00:00,https://www.biopharmcatalyst.com/company/KNTE/news/159347,0
SAVA,Alzheimer's disease,Phase 3,2023-09-18 00:00:00,"Phase 3 Data and Safety Monitoring Board (DSMB) recommended that both of Cassava Sciences' Phase 3 studies of simufilam continue as planned, without modification, noted September 18, 2023.",0
ARQT,Atopic Dermatitis - ages of 2-5 years old,Phase 3,2023-09-19 00:00:00,"Phase 3 top-line data reported that the trial met all its primary and secondary endpoints, noted September 19, 2023.",0
VIR,HIV T cell vaccine,Phase 1,2023-09-20 00:00:00,"Phase 1 dosing initiated, noted September 20, 2023.",0
ASND,Growth Hormone Deficiency - adults,Phase 3,2023-09-23 00:00:00,"Phase 3 resultspresented at ESPE 2023 showed that the majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit, noted September 23, 2023.",1
CLNN,Amyotrophic Lateral Sclerosis (ALS),Phase 2/3,2023-09-25 00:00:00,"Phase 2/3 post hoc results showed significantly improved survival with a 49% decreased risk of death for the covariate risk-adjusted analyses compared to the largest U.S. clinical database of previous amyotrophic lateral sclerosis (ALS) trials (PRO-ACT), noted September 25, 2023.",1
NVS,Gastroenteropancreatic neuroendocrine tumors (GEP-NETs),Phase 3,2023-09-25 00:00:00,"Phase 3 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR), noted September 25, 2023.",1
CADL,Non-small cell lung cancer (NSCLC),Phase 2,2023-09-26 00:00:00,"Phase 2 initial data suggests 12-month survival is consistent with an increased tail on the maturing survival curve, noted September 26, 2023.",0
LUMO,Pediatric Growth Hormone Deficiency (PGHD),Phase 2,2023-09-26 00:00:00,"Phase 2 interim data analysis reported that LUM-201 restored GH secretion to similar levels seen in normally growing children, noted September 26, 2023.",0
CRDF,Pancreatic ductal adenocarcinoma (PDAC),Phase 2,2023-09-26 00:00:00,"Phase 2 additional data reported an objective response rate (ORR) of 19% and median progression-free survival (mPFS) of 5.0 months, noted September 26, 2023.",0
CALT,Alport Syndrome,Phase 2,2023-09-27 00:00:00,"Phase 2 to be intiated in 4Q 2023. FDA granted Orphan Drug Designation, noted September 27, 2023.",0
BLRX,First-line pancreatic ductal adenocarcinoma (PDAC),Phase 2,2023-09-28 00:00:00,"Phase 2 trial data presented at the AACR Special pancreatic cancer conference reported that 6 patients (55%) experienced a partial response (PR) of which 4 (36%) were confirmed PRs with one patient experiencing resolution of the hepatic (liver) metastatic lesion, noted September 28, 2023.",1
BNOX,Post-Traumatic Stress Disorder (PTSD),Phase 2b,2023-09-28 00:00:00,"Phase 2b topline data met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements in depressive symptoms and sleep, noted September 28, 2023.",1
IMGN,Cancer - ovarian cancer and relapsed endometrial cancer,Phase 3,2023-09-28 00:00:00,"Additional Phase 3 data reported at ESGO noted that in patients with prior PARPi, ORR in the ELAHERE arm was 45%, including 7 CRs, compared to 17%, with no CRs, in the IC chemotherapy arm, noted September 28, 2023.",0
NBTX,Pancreatic cancer,Phase 1,2023-09-28 00:00:00,"Phase 1 data reported a 92.3% local disease control rate (12/13) and a median Overall Survival of 21 months, noted September 28, 2023.",0
RHHBY,Relapsed or refractory multiple myeloma,Phase 3,2023-09-29 00:00:00,"Phase 3 data reported that it showed improvement in median PFS of 9.9 months compared to 5.8 months with the combination of study comparator pomalidomide and dexamethasone; however, the results did not reach statistical significance, noted September 29, 2023.",1
SNDX,Relapsed/refractory (R/R) acute leukemias,Phase 2,2023-10-02 00:00:00,"Phase 2 trial met its primary endpoint at the protocol-defined interim analysis stage with a complete remission (CR) or a CR with partial hematological recovery (CRh) rate of 23% among the 57 efficacy evaluable patients in the pooled KMT2Ar acute leukemia cohort, noted October 2, 2023.",1
IKT,Multiple System Atrophy (MSA),Phase 2,2023-10-04 00:00:00,"Orphan Drug Designation granted by FDA on October 4, 2023.",0
MYMD,Sarcopenia and frailty,Phase 2,2023-10-04 00:00:00,"Phase 2 new data showed statistically significant results across Cohort 4 (1050mg), noted October 4, 2023.",1
BTAI,Solid Tumors,Phase 2,2023-10-10 00:00:00,"Phase 2 trial showed a median OS of 13.6 months and a 12-month survival rate of 56.5%., noted October 10, 2023.",1
CAPR,Duchenne Muscular Dystrophy (DMD),Phase 2,2023-10-10 00:00:00,"Phase 2 data presented at the World Muscle Society reported that the mean PUL 2.0 decline after 24-months of treatment with CAP-1002 was 2.8 points versus a 7.7-point decline on average observed over 24-months in the placebo, noted October 10, 2023.",1
GRTS,COVID-19 vaccine,Phase 1,2023-10-11 00:00:00,"Phase 1 data reported that all doses were well tolerated in both HIV-negative participants and PLWH irrespective of SARS-CoV-2 serostatus at baseline, noted October 11, 2023.",1
HALO,Multiple sclerosis (MS) or primary progressive MS,Phase 3,2023-10-11 00:00:00,"Phase 3 data reported that treatment was comparable to IV infusion in providing rapid and sustained depletion of B cells and near-complete suppression of MRI lesion activity in the brain over 24 weeks, noted October 11, 2023.",1
PDSB,Metastatic Prostate Cancer,Phase 1,2023-10-11 00:00:00,"First in human safety and immune data presented at Cytokines reported a decrease in PSA levels, and that all doses of the combination were well-tolerated with one patient experiencing Grade 4 neutropenia, noted October 11, 2023.",1
TEVA,Inflammatory conditions,CRL,2023-10-12 00:00:00,"CRL received October 12, 2023.",0
ALVO,Inflammatory conditions,CRL,2023-10-12 00:00:00,"CRL received October 12, 2023.",0
RLAY,Cholangiocarcinoma (CCA),Phase 1,2023-10-12 00:00:00,"Phase 1 data from non-CCA expansion cohort presented at AACR-NCI-EORTC reported a 35% overall response rate (ORR), and nine of 26 patients experienced a partial response (PR), noted October 12, 2023.",1
INCY,Hidradenitis suppurativa,Phase 2,2023-10-12 00:00:00,"Phase 2 secondary analysis presented at EADV reported that a large proportion of patients who received any dose of povorcitinib from Day 1 achieved T VASI50 (37.0% 45.2%) and F VASI75 (48.4% 58.6%) responses at Week 52, noted October 12, 2023.",1
NUVL,ALK non-small cell lung cancer (NSCLC),Phase 1,2023-10-13 00:00:00,"Phase 1 trial showed preliminary signs of activity observed in heavily pre-treated patients with ALK-positive NSCLC, including in subgroups of patients who have previously received a 2nd generation ALK TKI and lorlatinib, have brain metastases, or have single or compound ALK resistance mutations, noted October 13, 2023.",1
LLY,Atopic Dermatitis,Phase 1,2023-10-13 00:00:00,"Phase 1b data presented at EADV 2023 showed dose-dependent efficacy reported across all endpoints for REZPEG demonstrating a rapid onset of action and continuing benefit for 36 weeks after 12-week treatment period, noted October 13, 2023.",1
TRVI,Prurigo Nodularis (PN),Phase 2/3,2023-10-13 00:00:00,"Phase 2/3 long-term data also supports the continued effectiveness of Haduvio in reducing itch over 52 weeks for the participants who remained in the study, noted October 13, 2023.",1
IMUX,Relapsing-remitting multiple sclerosis (RMS),Phase 2,2023-10-13 00:00:00,"Phase 2 data presented at ECTRIMS reported that VidoCa was associated with a Nfl reduction from baseline up to W6 of -3% for the pooled 30 and 45mg VidoCa group compared to +2.5% for placebo, and up to W24 of -19% and +7%, respectively, noted October 13, 2023.",1
KOD,Diabetic Macular Edema (DME),Phase 3,2023-10-13 00:00:00,"Phase 3 data presented at the Retina Society meeting reported that 1/2 of patients achieved 6-month dosing at the primary endpoint, noted October 13, 2023.",1
MOR,Crohn's disease,Phase 3,2023-10-16 00:00:00,"Phase 3 data reported that in the combination 54% of patients reached a clinical remission, noted October 16, 2023.",1
APRE,Solid tumors,Phase 1/2,2023-10-16 00:00:00,"Phase 1/2a data presented at AACR-NCI-EORTC reported that no dose-limiting toxicities have been reported to date with persistent tumor-reducing effect, noted October 16, 2023.",1
REGN,Stage II to IV Cutaneous Squamous Cell Carcinoma (CSCC),Phase 2,2023-10-16 00:00:00,"Phase 2 data from ESMO reported a median duration of follow-up was 18.7 months, and 1 of 10 pts with MPR experienced recurrence, noted October 16, 2023.",0
ZLAB,Non-small cell lung cancer (NSCLC),Phase 3,2023-10-16 00:00:00,"Phase 3 data from ESMO abstract reported that quality of life data showed no statistically significant difference between patients who received TTFields therapy together with standard systemic therapies, noted October 16, 2023.",1
NVCR,Non-small cell lung cancer (NSCLC),Phase 3,2023-10-16 00:00:00,"Phase 3 data from ESMO abstract reported that quality of life data showed no statistically significant difference between patients who received TTFields therapy together with standard systemic therapies, noted October 16, 2023.",1
VECT,Short bowel syndrome - colon-in-continuity,Phase 2,2023-10-16 00:00:00,"Additional Phase 2 data reported that 33% of the patients achieving clinical response and PS volume reduction reached a statistically significant 40% at week 24 and the effect was maintained with a 52% volume reduction at week 52, noted October 16, 2023.",1
EVLO,"Psoriasis, healthy volunteers",Phase 2,2023-10-17 00:00:00,"Phase 2 study did not achieve its primary endpoint, noted October 17, 2023.",1
GMDA,Follicular and diffuse large B cell lymphomas,Phase 1,2023-10-17 00:00:00,"Phase 1 data showed promising early evidence of anti-tumor activity in patients with relapsed/refractory B cell non-Hodgkin lymphoma, noted October 16, 2023.",1
BOLT,Solid Tumors,Phase 1/2,2023-10-17 00:00:00,"Phase 1/2 initiated, noted October 17, 2023.",0
BMEA,Acute myeloid leukemia (AML),Phase 1,2023-10-17 00:00:00,"Phase 1 dosing initiated, noted October 17, 2023.",0
VIGL,Healthy volunteers,Phase 1,2023-10-17 00:00:00,"Phase 1 trial dosing initiated, noted October 17, 2023.",0
RHHBY,Non-small cell lung cancer (NSCLC),Phase 3,2023-10-18 00:00:00,"Phase 3 data reported that treatment reduces the risk of disease recurrence or death by 76%, noted October 18, 2023.",1
FGEN,Anaemia of myelodysplastic syndromes (MDS),Phase 3,2023-10-20 00:00:00,"Phase 3 data presented at ESMO reported that treatment demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of pathologic complete response (pCR) versus neoadjuvant chemotherapy alone, noted October 20, 2023.",1
AMAM,PSMA Expressing Tumors,Phase 1,2023-10-20 00:00:00,"Phase 1 data presented at ESMO reported that 52% (12/23) of patients experienced a ≥50% PSA reduction, and ≥90% PSA reduction observed in 6% (1/16) and 36% (5/14) of patients at 1.4 mg/kg (Cohort 4) and 2.0 mg/kg (Cohort 6), respectively, noted October 20, 2023.",1
BGNE,Gastric/gastroesophageal junction adenocarcinoma (G/GEJC),Phase 1/2,2023-10-20 00:00:00,"Phase 1b/2 data presented at ESMO reported that the confirmed objective response rate by investigator (INV) was 75.8% and median progression-free survival was 16.7 months, noted October 20, 2023.",1
KURA,Head and neck squamous cell carcinomas (HNSCC),Phase 2,2023-10-21 00:00:00,"Phase 2 data presented at ESMO reported that the Tipifarnib ORR was higher in 2L setting than 3L+ setting (29% vs. 15%), noted October 21, 2023.",1
PFE,"Claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma",Phase 3,2023-10-21 00:00:00,"Phase 3 data presented at ESMO reported that median PFS was 11.0 vs 8.9 mo and median OS was 18.2 vs 15.6 mo, noted October 21, 2023.",1
ALPMY,"Claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma",Phase 3,2023-10-21 00:00:00,"Phase 3 data presented at ESMO reported that median PFS was 11.0 vs 8.9 mo and median OS was 18.2 vs 15.6 mo, noted October 21, 2023.",1
AYLA,Desmoid tumors,Phase 2/3,2023-10-23 00:00:00,"Phase 2 data presented at ESMO showed that 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population, AL102 1.2 mg once daily treatment resulted in 88% reduction in tumor volume and 85% reduction in T2W signal intensity, noted October 23, 2023.",1
AZN,Untreated advanced or metastatic triple negative breast cancer (TNBC),Phase 1/2,2023-10-23 00:00:00,"Phase 1b/2 data reported a confirmed objective response rate (ORR) of 79% (95% confidence interval [CI]: 67-88) including six complete responses (CRs) and 43 partial responses (PRs), noted October 23, 2023.",0
AZN,Endometrial cancer (EC),Phase 3,2023-10-23 00:00:00,"Phase 3 results presented at ESMO reported statistically significant and clinically meaningful PFS benefit vs CP in the ITT population, with the interim OS data being immature (27.7%) yet with a trend towards benefit, noted October 21, 2023.",1
BMY,Non-small cell lung cancer (NSCLC),Phase 3,2023-10-23 00:00:00,"Phase 3 data presented at ESMO reported that 3-y EFS and OS rates were 72% vs 47% and 85% vs 66%, respectively, noted October 23, 2023.",1
AZN,"HR Positive, HER2 Negative Breast Cancer",Phase 3,2023-10-23 00:00:00,"Phase 3 data presented at ESMO showed reduction of the risk of disease progression or death by 37%, providing a 2-month median PFS benefit, and was well tolerated in post-endocrine therapy setting, noted October 23, 2023.",1
BOLT,"HER2-Expressing Solid Tumors, gastric cancer, including gastroesophageal junction cancer",Phase 2,2023-10-23 00:00:00,"Phase 2 updated safety data presented at ESMO supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D), noted October 23, 2023.",1
GLTO,Non-small cell lung cancer (NSCLC),Phase 2a,2023-10-23 00:00:00,"Phase 2a data reported that the objective tumor responses (defined as partial responses per RECIST criteria 1.1) were observed in three of five patients (60%) who received GB1211 for at least three weeks, noted October 23, 2023",1
RNAZ,Metastatic solid tumors,Phase 1a,2023-10-24 00:00:00,"Phase 0 preliminary data showed that radioactivity consistent with accumulation of TTX-MC138 was detected by noninvasive imaging in the regions of the metastatic lesions previously identified by fluorodeoxyglucose (FDG)/positron emission tomography (PET) (FDG/PET), noted October 24, 2023.",1
IMMP,Solid tumors,Phase 1,2023-10-24 00:00:00,"Phase 1 additional efficacy and tolerability data reported at ESMO showed strong 71.4% Overall Response Rate, 90.5% Disease Control Rate, 10.1-month median Progression Free Survival (PFS), and median Overall Survival (OS) that has not been reached, despite 81% of patients having low or negative PD-L1 expression, noted October 24, 2023.",1
ALNY,Alzheimer's Disease and Cerebral Amyloid Angiopathy,Phase 1,2023-10-25 00:00:00,"Phase 1 achieve sustained pharmacodynamic activity up to 10 months after administration, noted October 25, 2023.",1
PFE,"Influenza and COVID-19, Omicron BA.4/BA.5-adapted bivalent",Phase 1/2,2023-10-26 00:00:00,"Phase 1/2 data demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains, noted October 26, 2023.",1
ASND,Solid tumors,Phase 1/2,2023-10-26 00:00:00,"Phase 1/2 updated data presented at ESMO resulted in clinical responses demonstrated as monotherapy or in combination with checkpoint inhibitor, noted October 26, 2023.",1
EWTX,Duchenne Muscular Dystrophy (DMD),Approved,2023-10-26 00:00:00,"Approved October 26, 2023.",1
ABOS,Alzheimer’s disease (AD),Phase 1,2023-10-27 00:00:00,"Additional Phase 1 results shared at CTAD reported that statistically significant amyloid plaque reduction that was comparable to approved and in-review therapies at similar time points, was observed in higher dose cohorts, noted October 27, 2023",1
ALEC,Frontotemporal Dementia,Phase 3,2023-10-27 00:00:00,"Phase 3 target enrollment achieved, noted October 27, 2023.",1
RVPH,Schizophrenia,Phase 3,2023-10-30 00:00:00,"Phase 3 trial met primary endpoint, noted October 30, 2023.",0
FDMT,Fabry Disease,Phase 1/2,2023-10-30 00:00:00,"Phase 1/2 FDA meeting to lift clinical hold and continue trial developments, noted October 30, 2023.",1
CHRS,1L Metastatic Nasopharyngeal Carcinoma,Approved,2023-10-30 00:00:00,"Approved October 27, 2023.",1
SRPT,Duchenne muscular dystrophy,Phase 3,2023-10-30 00:00:00,"Phase 3 trial results showed that participants treated with ELEVIDYS (delandistrogene moxeparvovec-rokl) showed an increase on the North Star Ambulatory Assessment, a measure of motor function, compared to placebo-treated patients at 52 weeks, although the primary endpoint was not met, noted October 30, 2023.",1
GOVX,COVID-19 in immunocompromised patients,Phase 2,2023-10-30 00:00:00,"Phase 2 site expansion commenced, noted Otober 30, 2023.",0
CYBN,Major Depressive Disorder (MDD) and Alcohol use disorder (AUD),Phase 1/2,2023-10-31 00:00:00,"Phase 1/2a topline data reported that the reduction in major depressive disorder (""MDD"") symptoms, defined as change from baseline in MADRS total score, was superior in participants assigned to CYB003 compared to the participants who received placebo by 14.08 points, noted October 31, 2023.",1
INDP,Advanced/metastatic solid tumors,Phase 1,2023-10-31 00:00:00,"Phase 1 data abstract to be presented at SITC on November 4, 2023 noted that each of the first cohort participants experienced transient activation of biomarkers associated with innate and/or adaptive immune responses, and generally expected transient adverse events, noted October 31, 2024.",1
FDMT,Cystic fibrosis,Phase 2,2023-11-01 00:00:00,"Phase 2 Dose Expansion interim data presented at the North American Cystic Fibrosis Conference showed that it was generally well tolerated with no inflammation in any lung biopsy across Cohorts 1 and 2 (1E15 & 2E15 vg; n=7) with up to 17 months follow-up November 1, 2023.",1
PHAT,Erosive esophagitis / Gastroesophageal reflux disease (GERD),Approved,2023-11-01 00:00:00,"FDA Approved on November 1, 2023.",1
RANI,Neuroendocrine tumors (NETs) and acromegaly,Phase 1,2023-11-01 00:00:00,"Program discontinued, noted November 1, 2023.",-1
IPSC,Lymphoma or Indolent Lymphoma,Phase 1,2023-11-02 00:00:00,"Phase 1 data from ASH abstract reported that one patient achieved a complete response that is ongoing as of five months following their first CNTY-101 infusion, noted November 2, 2023.",1
NTLA,Transthyretin amyloidosis (ATTR),Phase 1,2023-11-02 00:00:00,"Phase 1 updated data from over 60 patients showed consistent, deep and durable serum TTR reduction achieved with a single dose of NTLA-2001, including in 29 patients who have now reached 12 months or more of follow-up, noted November 2, 2023.",1
REGN,Transthyretin amyloidosis (ATTR),Phase 1,2023-11-02 00:00:00,"Phase 1 updated data from over 60 patients showed consistent, deep and durable serum TTR reduction achieved with a single dose of NTLA-2001, including in 29 patients who have now reached 12 months or more of follow-up, noted November 2, 2023.",1
ACXP,C. difficile Infection,Phase 2b,2023-11-02 00:00:00,"Phase 2a and 2b data reported an observed Clinical Cure rate in the combined Phase 2 trials in patients with CDI was 96%, noted November 2, 2023.",1
MEIP,B-Cell Malignancies or Acute Myeloid Leukemia (AML),Phase 1,2023-11-02 00:00:00,"Phase 1 data from ASH abstract reported that at 200 mg, 5 of 10 AML pts (50%) had stable disease, noted November 2, 2023.",0
MOLN,Acute myeloid leukemia (AML),Phase 1,2023-11-02 00:00:00,"Phase 1 data from ASH abstract reported that one of the two patients evaluable for MP0533 antitumor activity in the third treatment cohort achieved a response, noted November 2, 2023.",1
EYEN,Mydriasis (office-based pupil dilation),Approved,2023-11-02 00:00:00,"FDA supplemental approval on November 1, 2023.",1
NRIX,B-cell malignancies / graft-versus-host disease,Phase 1a,2023-11-02 00:00:00,"Phase 1a data from ASH abstract reported that of three evaluable patients with CLL receiving the lowest dose of 50 mg, early signs of clinical activity were observed including one confirmed partial response and 2 patients with stable disease, noted November 2, 2023.",1
OMER,Paroxysmal nocturnal hemoglobinuria (PNH),Phase 1b,2023-11-02 00:00:00,"Phase 1b data from ASH abstract reported that mean Hgb increased from baseline by 3.1 g/dL at 4 weeks, and by 9.5 g/dL at the latest timepoint of 24 weeks, noted November 2, 2023.",0
SONN,Healthy volunteers,Phase 1,2023-11-02 00:00:00,"Phase 1 interim analysis presented at CTAD reported that in single doses up to 300 ng/kg and in patients with advanced cancer in repeated doses up to at least 540 ng/kg. Incorporation of a desensitizing first dose at 150-300 ng/kg and dosing every 3 weeks has been implemented to capitalize on the potential benefits of tachyphylaxis with rhIL-12, noted November 2, 2023.",1
TCRX,Hematologic malignancies,Phase 1,2023-11-02 00:00:00,"Phase 1 data from abstract reported that the safety analysis found expected post-HCT adverse events similar in treatment and control arms. Incidence of graft-versus-host disease (GvHD) was similar in control (3 events) and treatment arms, noted November 2, 2023.",1
ORIC,Multiple myeloma,Phase 1b,2023-11-02 00:00:00,"Phase 1b data from ASH abstract reported that ORIC-533 was very well tolerated, with 5 patients experiencing a total of 10 treatment-related adverse events (TRAEs), noted November 2, 2023.",1
INKT,Solid Tumors,Phase 1,2023-11-03 00:00:00,"Phase 1 trial of agenT-797 alone or in combination showed durable clinical benefit, including: Clinical response in MSI-high 3L gastric cancer patient after failure on pembrolizumab and nivolumab/FOLFOX. Long-term disease stabilization (n=10), including in testicular cancer (SD 9 months) and anti-PD-1 relapsed/refractory non-small-cell lung cancer (SD > 10 months). Tolerable safety profile with no dose-limiting toxicities and no grade >3 neurotoxicity or cytokine release syndrome, noted November 3, 2023.",1
KA,Solid tumors,Phase 1/2,2023-11-03 00:00:00,"Phase 1/2 biomarker data to be presented at SITC, noted Noember 3 2023.",1
ELTX,Solid Tumors,Phase 1/2,2023-11-03 00:00:00,"Phase 1/2 data presented at SITC reported that 87% (20/23) had direct ex vivo mKRAS-specific T cell responses, and 100% (23/23) had in vitro stimulated responses, noted November 3, 2023.",1
